Omnicell (OMCL) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 20, 2015	Jun. 30, 2014
Entity [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926326
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$1
Entity Common Stock, Shares Outstanding		36,166,305
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$125,888	$104,531
Accounts receivable, net of allowances of $1,206 and $490, respectively	82,763	58,597
Inventories, net	31,554	31,457
Prepaid expenses	23,518	18,883
Deferred tax assets	12,446	12,635
Other current assets	7,215	7,675
Total current assets	283,384	233,778
Property and equipment, net	36,178	35,254
Long-term net investment in sales-type leases	10,848	11,485
Goodwill	122,720	111,343
Intangible assets, net	82,667	81,602
Long-term deferred tax assets	1,144	1,102
Other long-term assets	23,273	17,937
Total assets	560,214	492,501
Current liabilities:
Accounts payable	19,432	16,471
Accrued compensation	19,874	19,604
Accrued liabilities	19,299	13,746
Deferred service revenue	25,167	22,626
Deferred gross profit	28,558	19,957
Total current liabilities	112,330	92,404
Long-term deferred service revenue	20,308	17,763
Long-term deferred tax liabilities	30,454	28,162
Other long-term liabilities	7,024	5,175
Total liabilities	170,116	143,504
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 100,000 shares authorized; 43,540 and 41,840 shares issued; 35,816 and 35,004 shares outstanding, respectively	43	41
Treasury stock at cost, 7,721 and 6,837 shares outstanding, respectively	-135,053	-110,962
Additional paid-in capital	457,436	421,232
Retained earnings	69,033	38,515
Accumulated other comprehensive income	-1,361	171
Total stockholders’ equity	390,098	348,997
Total liabilities and stockholders’ equity	$560,214	$492,501

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets Parenthetical (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Allowances	$1,206	$490
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	43,540,000	41,840,000
Common Stock, Shares, Outstanding	35,816,000	35,004,000
Treasury Stock, Shares	7,721,000	6,837,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product	$360,344	$307,189	$247,654
Services and other revenues	80,556	73,396	66,373
Total revenues	440,900	380,585	314,027
Cost of revenues:
Cost of product revenues	173,419	144,997	112,369
Cost of services and other revenues	33,621	32,189	31,070
Total cost of revenues	207,040	177,186	143,439
Gross profit	233,860	203,399	170,588
Operating expenses:
Research and development	27,802	29,105	23,726
Selling, general and administrative	156,475	138,995	119,736
Total operating expenses	184,277	168,100	143,462
Income from operations	49,583	35,299	27,126
Interest and other (expense), net	-1,079	-270	-51
Income before provision for income taxes	48,504	35,029	27,075
Provision for income taxes	17,986	11,050	10,897
Net income	$30,518	$23,979	$16,178
Net income per share:
Basic (in dollars per share)	$0.86	$0.69	$0.49
Diluted (in dollars per share)	$0.83	$0.67	$0.47
Weighted-average shares:
Basic (in shares)	35,650	34,736	33,307
Diluted (in shares)	36,622	35,777	34,213

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income Statement (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income	$30,518	$23,979	$16,178
Other comprehensive income (loss), net of reclassification adjustments:
Unrealized losses on securities	0	0	-1
Unrealized gains (losses) on foreign currency forward contracts	0	-65	65
Foreign currency translation adjustments	-1,532	105	66
Other comprehensive income (loss), net of tax:	-1,532	40	130
Comprehensive income	$28,986	$24,019	$16,308

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Earnings (Deficit) [Member]	Accumulated Other Comprehensive Income [Member]
In Thousands, unless otherwise specified
Stockholders' Equity, Beginning of period at Dec. 31, 2011	$282,914	$38	($77,637)	$362,154	($1,642)	$1
Shares of Treasury Stock, Beginning of period at Dec. 31, 2011			-5,054
Shares of Common Stock, Beginning of period at Dec. 31, 2011		38,236
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	16,178				16,178
Other comprehensive income	130					130
Shares repurchased (in shares)	-898		-898
Stock repurchases	-12,363		-12,363
Share-based compensation	9,214			9,214
Issuance of common stock under employee stock plans (in shares)		1,258
Issuance of common stock under employee stock plans	10,191	1		10,190
Tax payments related to restricted stock units	-1,241			-1,241
Income tax benefits from employee stock plans	2,527			2,527
Stockholders' Equity, End of period at Dec. 31, 2012	307,550	39	-90,000	382,844	14,536	131
Shares of Treasury Stock, End of period at Dec. 31, 2012			-5,952
Shares of Common Stock, Beginning of period at Dec. 31, 2012		39,493
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	23,979				23,979
Other comprehensive income	40					40
Shares repurchased (in shares)	-885		-885
Stock repurchases	-20,962		-20,962
Share-based compensation	11,151			11,151
Issuance of common stock under employee stock plans (in shares)		2,349
Issuance of common stock under employee stock plans	26,886	2		26,884
Tax payments related to restricted stock units	-2,223			-2,223
Income tax benefits from employee stock plans	2,576			2,576
Stockholders' Equity, End of period at Dec. 31, 2013	348,997	41	-110,962	421,232	38,515	171
Shares of Treasury Stock, End of period at Dec. 31, 2013	-6,837		-6,837
Shares of Common Stock, Beginning of period at Dec. 31, 2013		41,842
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,518				30,518
Other comprehensive income	-1,532					-1,532
Shares repurchased (in shares)	-884		-884
Stock repurchases	-24,091		-24,091
Share-based compensation	12,785			12,785
Issuance of common stock under employee stock plans (in shares)		1,695
Issuance of common stock under employee stock plans	21,795	2		21,793
Tax payments related to restricted stock units	-3,744			-3,744
Income tax benefits from employee stock plans	5,370			5,370
Stockholders' Equity, End of period at Dec. 31, 2014	$390,098	$43	($135,053)	$457,436	$69,033	($1,361)
Shares of Treasury Stock, End of period at Dec. 31, 2014	-7,721		-7,721
Shares of Common Stock, Beginning of period at Dec. 31, 2014		43,537

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Activities
Net income	$30,518	$23,979	$16,178
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	20,272	18,365	13,325
Loss on disposal of fixed assets	167	345	66
Impairment of software development costs and equity investments	350	1,759	0
Provision for receivable allowance	941	110	582
Share-based compensation expense	12,785	11,151	9,214
Income tax benefits from employee stock plans	5,370	2,576	2,527
Excess tax benefits from employee stock plans	-5,834	-3,673	-3,182
Provision for excess and obsolete inventories	542	856	394
Deferred income taxes	1,402	787	2,718
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable, net	-22,799	-3,609	-9,311
Inventories	1,418	-5,410	2,536
Prepaid expenses	-4,296	-3,491	-4,897
Other current assets	53	1,566	-1,114
Net investment in sales-type leases	1,048	1,723	-4,154
Other assets	297	630	-3,831
Accounts payable	1,611	-1,784	1,751
Accrued compensation	270	7,991	4,285
Accrued liabilities	5,512	1,758	674
Deferred service revenue	5,086	82	2,914
Deferred gross profit	8,601	-815	6,562
Other long-term liabilities	1,849	367	2,247
Net cash provided by operating activities	65,163	55,263	39,484
Investing Activities
Maturities of short-term investments	0	0	8,122
Acquisition of intangible assets and intellectual property	-327	-356	-373
Software development for external use	-10,353	-7,761	-5,028
Purchases of property and equipment	-11,922	-12,335	-15,120
Business acquisition, net of cash acquired	-20,723	0	-156,312
Net cash used in investing activities	-43,325	-20,452	-168,711
Financing Activities
Proceeds from issuances under stock-based compensation plans	21,795	26,886	10,190
Employees' taxes paid related to restricted stock units	-3,744	-2,223	-1,241
Common stock repurchases	-24,091	-20,962	-12,363
Excess tax benefits from employee stock plans	5,834	3,673	3,182
Net cash provided by (used in) financing activities	-206	7,374	-232
Effect of exchange rate changes on cash and cash equivalents	-275	33	10
Net increase (decrease) in cash and cash equivalents	21,357	42,218	-129,449
Cash and cash equivalents at beginning of period	104,531	62,313	191,762
Cash and cash equivalents at end of period	125,888	104,531	62,313
Supplemental cash flow information
Cash paid for interest	61	122	28
Cash paid for taxes, net of refunds	9,161	7,062	6,676
Supplemental disclosure of non-cash investing activities
Purchases of property and equipment	$273	$1,696	$0

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Business
	Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication, supply control systems and medication adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada. "Omnicell," "our," "us," "we," or the "Company" collectively refer to Omnicell, Inc. and its subsidiaries.
	Principles of consolidation
	The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The results of companies acquired during the year are included in the Consolidated Financial Statements from the effective date of acquisition.
	Use of estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes.
	Segment reporting change
	We modified our segment reporting structure to match our operating structure based on how our Chief Operating Decision Maker (“CODM”) views the business and allocates resources, beginning in the first quarter of 2014. The CODM function is our Chief Executive Officer. Retrospective adjustments of prior period financial information have been made to conform to the current period presentation. This change does not impact previously reported Consolidated Financial Statements of the Company. See Note 17, Segment Information, for additional information on our segment reporting change.
	Foreign currency translation
	We translate the assets and liabilities of our non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity.
	Revenue recognition
	We earn revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues related to consumable products are reported net of discounts provided to our customers. Our customer arrangements typically include one or more of the following deliverables:
	Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
	Software. Additional software applications that enable incremental functionality of our equipment.
	Installation. Installation of equipment as integrated systems at customers' sites.
	Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
	Professional services. Other customer services, such as training and consulting.
	We recognize revenue when the earnings process is complete, based upon our evaluation of whether the following four criteria have been met:
	Persuasive evidence of an arrangement exists. We use signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, we use a signed services agreement and a statement of work to evidence an arrangement.
	Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that we have delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, we recognize revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install our equipment at the end-user customer facility, we recognize revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met since we do not allow for rights of return or refund. For new distributors, where we have not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install our equipment at the end-user facility. For the sale of consumable blister cards, we recognize revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from our facilities. Assuming all other revenue criteria are met, we recognize revenue for support services ratably over the related support services contract period. We recognize revenue on training and professional services as they are performed.
	Fee is fixed or determinable. We assess whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. We have established a history of collecting under the original contract without providing concessions on payments, products or services.
	Collection is probable. We assess the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in our judgment, collection of a fee is not probable, we defer the revenue until the uncertainty is removed, which generally means revenue is recognized upon our receipt of cash payment assuming all other revenue criteria are met. Our historical experience has been that collection from our customers is generally probable.
	In arrangements with multiple deliverables, assuming all other revenue criteria are met, we recognize revenue for individual delivered items if they have value to the customer on a standalone basis. We allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires us to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, we use vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. We consider VSOE to exist when approximately 80% or more of our standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). We have established VSOE of the selling price for our post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, our offerings and market strategy differ from those of our competitors, such that we cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, we use our best estimates of selling prices ("BESP"). We determine BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. We regularly review and update our VSOE and BESP information.
	The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement.
	We also use the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered.
	A portion of our sales are made through multi-year lease agreements. Under sales-type leases, we recognize revenue for our hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once our installation obligations have been met. We optimize cash flows by selling a majority of our non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold. Some of our sales-type leases, mostly those relating to U.S. government hospitals, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method.
	Financial Instruments
	For assets and liabilities measured at fair value, such amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level. The following methods were used to estimate the fair value of each class of financial instruments for which it is practical to estimate that value:
	Cash equivalents. We classify investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. Our cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality, and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest. We have not experienced any credit losses from our cash investments.
	Marketable securities. Our marketable securities and investments are classified as available-for-sale, and unrealized gains and losses, net of tax, are included in accumulated other comprehensive income.
	Equity investments. We make equity investments in privately-held companies whose businesses are complementary to our business. The investment in which we hold less than 20% of the voting stock outstanding and do not exert significant influence is accounted for under the cost method of accounting. The cost amount of this investment was $0.4 million as of December 31, 2014 and December 31, 2013, and was no longer realizable as of December 31, 2014 and therefore considered impaired as discussed in Note 9, Other Assets. We invested $0.9 million to purchase 15% of our United Kingdom automation and analytics products distributor’s outstanding equity. We record this investment under the equity method of accounting as we have the right to appoint a member to this company's board of directors as well as certain other voting rights and, therefore, we believe we have the ability to exert significant influence over this distributor's operations. Our proportionate equity share of the income of this distributor, recognized in interest and other income, net was immaterial for the years ended December 31, 2014, December 31, 2013 and December 31, 2012. Our equity investments are included in other long-term assets. We assess the recoverability of these investments by reviewing various indicators for other-than-temporary impairment.
	Foreign currency forward contracts. We enter into foreign currency forward contracts to protect our business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and our foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. We had no foreign currency forward contracts which qualify for hedge accounting as of December 31, 2014 and December 31, 2013, and had no foreign currency forward contracts as of December 31, 2014.
	Debt. Our debt includes a $75 million revolving credit facility. Borrowings under our revolving credit facility would be recognized at cost plus accrued interest based upon stated interest rates. We have not yet drawn any funds under the credit facility to date.
	Accounts receivable and notes receivable (net investment in sales-type leases)
	We actively manage our accounts receivable to minimize credit risk. We typically sell to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. We continually monitor and evaluate the collectability of our trade receivables based on a combination of factors. We record specific allowances for doubtful accounts when we become aware of a specific customer's impaired ability to meet its financial obligation to us, such as in the case of bankruptcy filings or deterioration of financial position. There were no significant customers that accounted for more than 10% of our accounts receivable as of December 31, 2014 and December 31, 2013.
	Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when we make a final determination that there is no reasonable expectation of recovery. Estimates are used in determining our allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While we believe that our allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future.
	The retained in-house leases discussed above are considered financing receivables. Our credit policies and evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Financing receivables which are reserved are generally transferred to cash-basis accounting so that revenue is recognized only as cash is received. However, the cash basis accounts continue to accrue interest.
	Sales of accounts receivable
	We record the sale of our accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets. We transferred non-recourse accounts receivable totaling $62.0 million, $41.3 million and $60.9 million as of December 31, 2014, December 31, 2013 and December 31, 2012, respectively, which approximated fair value, to leasing companies on a non-recourse basis. Accounts receivable included approximately $1.1 million, $0.1 million and $0.7 million due from third-party leasing companies for transferred non-recourse accounts receivable as of December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
	Inventory
	Inventories are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or market. Cost elements included in inventory are direct labor and materials plus applied overhead. We routinely assess on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. We write down our inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than we projected, additional inventory write-downs may be required.
	Property and equipment
	Property and equipment less accumulated depreciation are stated at historical cost. Our expenditures for property and equipment are for computer equipment and software used in the administration of our business, and for leasehold improvements to our leased facilities. We also develop molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 - 7 years
	Equipment	3 - 12 years
	We capitalize costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Software obtained for internal use has generally been enterprise-level business and finance software that we customize to meet our specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred. We capitalized $3.9 million and $4.8 million of costs related to the application development of enterprise-level software that was included in property and equipment during the years ended December 31, 2014 and December 31, 2013, respectively.
	Software development costs
	We capitalize software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. We establish feasibility when we complete a working model and amortize development costs over the estimated lives of the related products ranging from three to five years. We capitalized software development costs of $10.4 million and $7.8 million which are included in other assets as of December 31, 2014 and December 31, 2013, respectively. We recorded $4.4 million, $3.2 million and $2.3 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively. All development costs prior to the completion of a working model are recognized as research and development expense.
	Business Combinations
	We use the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in our Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
	Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names.
	Goodwill and intangible assets
	Goodwill. We review goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. Our reporting units are the same as our operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. This initial assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this initial qualitative assessment indicates that it is more likely than not that impairment exists, or if we decide to bypass this option, we proceed to a two-step impairment test. The first step ("Step 1") involves a comparison between the estimated fair values of our reporting units with their respective carrying amounts including goodwill. The methods for estimating reporting unit values include asset and liability fair values and other valuation techniques, such as discounted cash flows and multiples of earnings or revenues. If the carrying value exceeds estimated fair value, there is an indication of potential impairment, and the second step is performed to measure the amount of impairment. The second step involves calculating an implied fair value of goodwill by measuring the excess of the estimated fair value of the reporting units over the aggregate estimated fair values of the individual assets less liabilities. If the carrying value of goodwill exceeds the implied fair value of goodwill, an impairment charge is recorded for the excess.
	To determine each reporting units’ fair value in the second step, we would use the income approach which is based on the estimated discounted future cash flows of that reporting unit. The estimated fair value of each reporting unit under the income approach is corroborated with the market approach, which measures the value of a business through an analysis of recent sales or offerings of a comparable entity. We also consider our market capitalization on the date of the analysis to ensure the reasonableness of the sum of our reporting units’ estimated fair value.
	Intangible assets. In connection with our acquisitions, we generally recognize assets for customer relationships, technology and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from 1 to 30 years. Amortization for technology is recognized in cost of product revenues, and amortization for customer relationships and trade names is recognized in selling, general and administrative expenses.
	We assess the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. Our cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of our intangible assets are subjective and are affected by changes to our business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of our assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on our operating results and financial condition.
	Valuation of share-based awards
	We account for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). We recognize compensation expense related to stock-based compensation, including the awarding of employee stock awards and restricted stock units, based on the grant date estimated fair value. We amortize the fair value of the employee stock awards on a straight-line basis over the requisite service period of the award, which is generally the vesting period. We estimate the fair value of stock-based compensation awards using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of our common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on our historical experience of employee stock option exercises, including forfeitures. The valuation assumptions we use in estimating the fair value of employee share-based awards may change in future periods. We calculate our pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718.
	Accounting for income taxes
	We record an income tax provision for the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provision for income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, we will incur a benefit or detriment on our income tax expense in the period of change. If we were to determine that all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
	In accordance with ASC 740, Income Taxes, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of U.S. GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results.
Deferred service revenue and deferred gross profit
Deferred service revenue and deferred gross profit arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. Our deferred gross profit, classified as a current liability, consists primarily of unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment and the unearned revenue for software licenses. Our deferred service revenue, separated into current and long-term liabilities, consists of the unearned portion of service contracts for which revenue is recognized over their duration.
Commissions
Sales commissions are incremental and directly related to customer sales contracts in which revenue is deferred. These commission costs are accrued and recorded in prepaid expenses upon execution of a non-cancelable customer contract and subsequently expensed in the period of revenue recognition.
Shipping costs
Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense. Shipping and handling expenses were $7.4 million, $6.1 million and $4.1 million for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
Recently adopted accounting standards
In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes: Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.
Recently issued authoritative guidance
In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, that requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers, and will replace most existing revenue recognition guidance in U.S. GAAP. The new standard is effective for us in the first quarter of 2017, and early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that the standard will have on our Consolidated Financial Statements and related disclosures.
There was no other recently issued authoritative guidance that has a material impact on our Consolidated Financial Statements through the reporting date.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations	Business Combinations
	2014 Acquisition Activity
	On August 22, 2014, we completed our acquisition of Surgichem, a wholly-owned subsidiary of Bupa Care Homes (CFG) Plc ("Bupa"). In exchange for all of the voting equity interests of the acquired company, we paid a total purchase price of $20.7 million in cash, net of $0.2 million of cash acquired. This acquisition will assist U.K. healthcare professionals and caregivers seeking to improve patient outcomes, reduce medication errors and lower costs by effectively managing compliance to prescribed medication regimes in their mission to extend patient health and satisfaction through convenient, effective medication adherence solutions. Surgichem is being integrated with Omnicell’s existing U.K. business, MTS, a leading supplier of medication adherence packaging solutions.
	The following table presents the purchase price allocation included in our Consolidated Balance Sheets:
		(In thousands)
	Cash	$	153
	Accounts receivable	2,462
	Inventory	2,190
	Deferred tax assets and other current assets	361
	Total current assets	$	5,166
	Property and equipment	164
	Intangibles	5,730
	Goodwill	12,112
	Total assets	$	23,172
	Current liabilities	1,191
	Long-term deferred tax liabilities	1,104
	Total purchase price	$	20,877
	Acquired intangible assets. The fair value of $5.4 million for acquired customer relationships was determined based on an income approach using the discounted cash flow method. The fair value of $0.3 million for the trade name was determined using the relief-from-royalty approach. Customer relationships are amortized over their estimated useful lives of 18 years and the trade name is amortized over its estimated useful life of approximately 1 year.
	Goodwill. The purchase price allocation resulted in goodwill of $12.1 million, which represents sales of future products and services and the assembled workforce of Surgichem. We believe the acquisition enhances Omnicell’s offerings and diversifies its revenue mix providing a more robust product and service solution to its current customers while expanding Omnicell’s international presence. We considered these factors as supporting the amount of goodwill recorded.
	The amortization of intangible assets and goodwill is not deductible for tax purposes.
	We incurred approximately $1.1 million in acquisition-related costs related to the Surgichem acquisition, offset by a $0.5 million expense reimbursement from Bupa for the year ended December 31, 2014. These costs are included in selling, general and administrative expenses in our Consolidated Statement of Operations.
	Surgichem generated revenue of $4.6 million and losses from operations of $0.1 million since the acquisition date for the year ended December 31, 2014. The total revenues of Surgichem were $13.3 million (including $4.6 million mentioned above) and $11.9 million for the years ended December 31, 2014 and December 31, 2013, respectively. Results of operations for Surgichem have been included as a part of our Medication Adherence segment, and supplemental pro forma results of operations for the prior periods have not been presented, as the effect of the acquisition was not material to our consolidated financial results.
	2012 Acquisition Activity
	On May 21, 2012, we completed our acquisition of MedPak Holdings, Inc. ("MedPak") pursuant to an Agreement and Plan of Merger ("Merger Agreement") under which Mercury Acquisition Corp, a newly formed Omnicell subsidiary, was merged with and into MedPak, with MedPak surviving the merger as a wholly-owned subsidiary of Omnicell. MedPak is the parent company of MTS, a worldwide provider of medication adherence packaging systems. Pursuant to the terms of the Merger Agreement, we paid $156.3 million in cash, net of $2.0 million cash acquired.
	The objective of the acquisition was to primarily align Omnicell with the long term trends of the healthcare market to manage the health of patients across the continuum of care. Omnicell and MTS bring capabilities to each other that strengthen the product lines and expand the medication management coverage of both companies.
	The following table presents the purchase price allocation included in our Consolidated Balance Sheets:
		(In thousands)
	Cash	$	2,000
	Accounts receivable	7,403
	Inventory	11,726
	Deferred tax assets and other current assets	2,894
	Total current assets	$	24,023
	Property and equipment	9,807
	Intangible assets	83,900
	Goodwill	82,800
	Other long-term assets	308
	Total assets	$	200,838
	Current liabilities	(7,917		)
	Long-term deferred tax liabilities	(33,386		)
	Other long-term liabilities	(1,223		)
	Total purchase price	$	158,312
	Identifiable intangible assets. Acquired technology relates to MTS’ products across all of its product lines that have reached technological feasibility, primarily the OnDemand technology. Trade names are primarily related to the MTS and OnDemand brand names. Customer relationships represent existing contracted relationships with pharmacies, institutional care facilities and others. Acquired technology, customer relationships, and trade names are amortized on a straight-line basis over their estimated useful lives, which range from 12 to 30 years.
	The estimated fair values of the acquired technology, trade names and customer relationships were primarily determined using either the relief-from-royalty or excess earnings methods. The interest rates utilized to discount net cash flows to their present values were determined after consideration of the overall enterprise rate of return and the relative risk and importance of the assets to the generation of future cash flows.
	The historical tax bases of the acquired assets and assumed liabilities, along with the tax attributes of the MTS companies, will carry over for income tax purposes. As the transaction was a cash-for-stock transaction, there is no tax basis in the acquired intangible assets. Accordingly, the acquisition accounting includes the establishment of net deferred tax liabilities of $33.4 million, resulting from book tax basis differences related to the intangible assets acquired, as well as to the step up in the value of fixed assets and inventory to their estimated fair values at the time of acquisition.
	The following represents the details of the acquired intangible assets:
		Intangible Assets			Useful Life
		Acquired			(Years)
		(In thousands, except for years)
	Trade name	$	6,800		12
	Customer relationships	50,500			28 to 30
	Acquired technology	26,600			20
	Intangibles acquired	$	83,900
	Goodwill. The purchase price allocation resulted in goodwill of $82.8 million. We believe the MTS acquisition enhances our offerings and diversifies our revenue mix, providing a more robust product and service solution to our current customers while expanding Omnicell’s international presence. We considered these factors as supporting the amount of goodwill recorded.
	We incurred approximately $3.2 million in acquisition-related costs for the year ended December 31, 2013. These costs are included in selling, general and administrative expenses in our Consolidated Statement of Operations.
	MTS generated revenue of $47.2 million and net income of $2.9 million since the acquisition date for the year ended December 31, 2012. Results of operations for MTS have been included as a part of our Medication Adherence segment, and supplemental pro forma results of operations for the prior periods have not been presented, as the effect of the acquisition was not material to our consolidated financial results.

Net_Income_Per_Share

Net Income Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share
	Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since the impact is anti-dilutive, these shares were excluded from the calculations of diluted net income per share.
	The calculation of basic and diluted net income per share is as follows:
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands, except per share data)
	Net income	$	30,518	$	23,979	$	16,178
	Weighted-average shares outstanding — basic	35,650		34,736		33,307
	Add: Dilutive effect of employee stock plans	972		1,041		906
	Weighted-average shares outstanding — diluted	36,622		35,777		34,213
	Net income per share — basic	$	0.86	$	0.69	$	0.49
	Net income per share — diluted	$	0.83	$	0.67	$	0.47
	Anti-dilutive weighted-average shares related to stock award plans	640		850		2,149

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	For assets and liabilities measured at fair value, such amounts are based on an expected exit price representing the amount that would be received from the sale of an asset or paid to transfer a liability in a transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs used in valuation techniques are assigned a hierarchical level. The following methods were used to estimate the fair value of each class of financial instruments for which it is practical to estimate that value:
	•	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	•	Level 2: Observable inputs that reflect quoted prices for identical assets or liabilities in markets that are not active, quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the assets or liabilities, or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	•	Level 3: Unobservable inputs reflecting our own assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	Assets Measured at Fair Value on a Recurring Basis
	Cash equivalents. Cash equivalents consist of money market funds that are classified as Level 1, and have an original maturity of three months or less, and therefore the carrying amount is a reasonable estimate of fair value due to the short duration to maturity.
	There have been no transfers between fair value measurement levels during 2014 and 2013. The following table summarizes our assets measured at fair value on a recurring basis using Level 1 inputs within the fair value hierarchy:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Cash	$	61,311	$	38,823
	Cash equivalents	64,577		65,708
	Total cash and cash equivalents	$	125,888	$	104,531
	Net investment in sales-type leases. The carrying amount of our sales-type lease receivables is a reasonable estimate of fair value as the unearned interest income is immaterial.
	Assets and liabilities measured and recorded at fair value on a nonrecurring basis
	See Note 2, Business Combinations, for the fair value of intangible assets acquired that were calculated using an income approach valuation technique based on Level 3 unobservable inputs.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consist of the following components:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Raw materials	$	8,254	$	10,765
	Work in process	64		534
	Finished goods	23,236		20,158
	Total inventories, net	$	31,554	$	31,457
	Dependence on suppliers
	We have a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract with our supplier may be terminated by either the supplier or by us without cause and at any time upon delivery of two months' notice. Purchases from this supplier were $34.5 million, $29.2 million and $23.8 million for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consist of the following assets:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Equipment	$	42,829		$	40,180
	Furniture and fixtures	5,689			5,260
	Leasehold improvements	8,701			7,394
	Purchased software	28,920			20,199
	Construction in progress	1,538			2,649
		87,677			75,682
	Accumulated depreciation and amortization	(51,499		)	(40,428		)
	Total property and equipment, net	$	36,178		$	35,254
	Depreciation and amortization of property and equipment was $11.3 million, $10.9 million and $8.0 million for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.

Net_Investment_in_SalesType_Le

Net Investment in Sales-Type Leases	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases
	The terms of our sales-type leases are generally up to five years in length. Sales-type lease receivables are collateralized by the underlying equipment. Net investment in sales-type leases consist of the following components:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Net minimum lease payments to be received	$	17,616		$	18,172
	Less: unearned interest income portion	(1,131		)	(1,455		)
	Net investment in sales-type leases	16,485			16,717
	Less: short-term portion	(5,637		)	(5,232		)
	Long-term net investment in sales-type leases	$	10,848		$	11,485
	We evaluate our sales-type leases individually and collectively for impairment, and recorded a collective allowance for credit losses of $0.2 million and $0.2 million as of December 31, 2014 and December 31, 2013, respectively.
	The minimum lease payments under sales-type leases are as follows:
		December 31,
		2014
		(In thousands)
	2015	$	6,188
	2016	4,832
	2017	3,803
	2018	2,174
	2019	619
	Total	$	17,616

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	Goodwill
	The changes in the carrying amount of goodwill are as follows:
		Automation and		Medication			Total
		Analytics		Adherence
		(In thousands)
	Net balance as of December 31, 2012	$	28,543	$	82,864		$	111,407
	Additions	—		—			—
	Adjustments (1)	—		(64		)	(64		)
	Net balance as of December 31, 2013	$	28,543	$	82,800		$	111,343
	Additions (2)	—		12,112			12,112
	Adjustments (3)	—		(735		)	(735		)
	Net balance as of December 31, 2014	$	28,543	$	94,177		$	122,720
	_________________________________________________
	(1)	Goodwill includes an immaterial adjustment related to the MTS acquisition in May 2012.
	(2)	Additions to goodwill as a result of the Surgichem acquisition in August 2014, including a $0.1 million adjustment to the purchase price in the fourth quarter of 2014.
	(3)	Adjustments reflect foreign currency exchange rate fluctuations.
	Effective in the first quarter of 2014, we modified our segment reporting structure to match our new operating structure. Our reporting units for goodwill are the same as our reportable operating segments. See Note 17, Segment Information, for information regarding the changes related to segment information.
	Intangible assets, net
		December 31, 2014									December 31, 2013
		Gross		Accumulated			Net			Useful Life	Gross Carrying		Accumulated			Net		Useful Life
		Carrying		Amortization			Carrying			(Years)	Amount		Amortization			Carrying		(Years)
		Amount					Amount									Amount
		(In thousands, except for years)
	Customer relationships	$	60,150	$	(7,919	)	$	52,231		30-May	$	54,730	$	(5,236	)	$	49,494	30-May
	Acquired technology	27,580		(4,068		)	23,512			20-Mar	27,580		(2,598		)	24,982		20-Mar
	Trade names	7,110		(1,576		)	5,534			12-Jan	6,890		(1,003		)	5,887		12-Mar
	Patents	1,655		(265		)	1,390			20	1,493		(254		)	1,239		20
	Non-compete agreements	—		—			—			—	60		(60		)	—		3
	Total intangibles assets, net	$	96,495	$	(13,828	)	$	82,667			$	90,753	$	(9,151	)	$	81,602
	We capitalized third-party costs associated with internally-developed patents of $0.3 million, $0.4 million and $0.4 million as of December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
	Amortization expense of intangible assets was $4.6 million, $4.3 million and $2.9 million for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
	Total future amortization expense for intangible assets is as follows:
		December 31,
		2014
		(In thousands)
	2015	$	4,679
	2016	4,354
	2017	4,267
	2018	4,113
	2019	4,063
	Thereafter	61,191
	Total	$	82,667

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	Other Assets
	Other assets consist of the following:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Capitalized software development costs, net of accumulated amortization of $14,918 and $10,547, respectively, and accumulated impairment (1)	$	19,643	$	13,660
	Technology license	1,678		2,350
	Long-term deposits	860		682
	Other long-term assets (2)	1,092		1,245
	Total other long-term assets	$	23,273	$	17,937
	_________________________________________________
	(1)	In the first quarter of 2013, we reorganized our management team as part of the continuing integration of MTS, including the software development department within the Medication Adherence segment. At this time, $1.8 million was capitalized as software development costs associated with a software solution that was intended to assist pharmacies in manual packaging of prescriptions. Our management team reassessed the viability of this project and the net realizable value of the capitalized costs in light of their decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities were needed to be added to the product before commercialization. This redesign was intended to provide a more robust global platform providing larger scalability and significant functionality not contained in the then-current beta version. We determined we could no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we abandoned the project and wrote off its net book value of $1.8 million, equating to $0.03 per diluted share, net of tax, which was recorded as an expense of research and development in our Consolidated Statements of Operations.
	(2)	Other long-term assets primarily include our equity investments. In the fourth quarter of 2014, we determined our equity investment accounted for under the cost method of accounting is no longer considered realizable, and therefore wrote off its net book value of $0.4 million as a non-operating expense in our Consolidated Statements of Operations.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities
	Accrued liabilities consist of the following:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Rebates and lease buyouts	$	6,512	$	1,699
	Advance payments from customers	4,834		4,971
	Group purchasing organization fees	3,475		2,324
	Technology license purchase obligation	—		1,500
	Taxes payable	2,181		1,664
	Other accrued liabilities	2,297		1,588
	Total accrued liabilities	$	19,299	$	13,746

Deferred_Gross_Profit

Deferred Gross Profit	12 Months Ended
	Dec. 31, 2014
Revenue Recognition [Abstract]
Deferred Gross Profit	Deferred Gross Profit
	Deferred gross profit consists of the following:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Sales of medication and supply dispensing systems including packaging equipment (1)	$	36,947		$	29,040
	Less: cost of revenues, excluding installation costs	(8,389		)	(9,083		)
	Total deferred gross profit	$	28,558		$	19,957
	_________________________________________________
	(1)	Delivered and invoiced, pending installation.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments
	Lease commitments
	We lease our buildings under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. Rent expense was $6.8 million, $6.9 million and $5.7 million for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
	The minimum future payments on non-cancelable operating leases are as follows:
		December 31,
		2014
		(In thousands)
	2015	$	5,637
	2016	5,590
	2017	4,873
	2018	4,711
	2019	4,836
	Thereafter	12,991
	Total minimum future lease payments	$	38,638
	Purchase obligations
	We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. These amounts are associated with agreements that are enforceable and legally binding. Our purchase obligations to our contract manufacturers and suppliers within the next year were $9.3 million as of December 31, 2014.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies
	Legal Proceedings
	On September 12, 2014, MV Circuit Design, Inc., an Ohio company ("MV Circuit"), brought an action to correct the inventorship of certain patents owned by Omnicell, as well as related state-law claims against Omnicell in the Northern District of Ohio (Case No. 1:14-cv-02028-DAP) regarding allegations of fraud in the filing and prosecution of U.S. Patent Nos. 8,180,485, 8,773,270, 8,812,153, PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505 (the “Action”). On November 14, 2014, we filed a motion to dismiss the Action. MV Circuit Design responded to our motion to dismiss on January 29, 2015, and we replied in support of our motion to dismiss on February 17, 2015. The court has not yet ruled on the motion to dismiss. No schedule has yet been set by the court for the case. We intend to defend the matter vigorously.
	As required under ASC 450, Contingencies, we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described above based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses.
	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2014 and December 31, 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The following is a geographical breakdown of income before the provision for income taxes:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	Domestic	$	48,327		$	34,678		$	25,794
	Foreign	177			351			1,281
	Income before provision for income taxes	$	48,504		$	35,029		$	27,075
	The provision for income taxes consists of the following:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	Current:
	Federal	$	14,063		$	8,218		$	7,181
	State	2,274			1,621			1,006
	Foreign	192			447			154
	Total current income taxes	16,529			10,286			8,341
	Deferred:
	Federal	1,603			1,287			2,169
	State	84			(263		)	651
	Foreign	(230		)	(260		)	(264		)
	Total deferred income taxes	1,457			764			2,556
	Total provision for income taxes	$	17,986		$	11,050		$	10,897
	The provision for income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	U.S. federal tax provision at statutory rate	$	16,998		$	12,260		$	9,476
	State taxes	1,533			883			1,077
	Non-deductible expenses	809			297			530
	Acquisition costs	229			—			431
	Share-based compensation expense	461			407			403
	Research tax credits	(818		)	(1,430		)	—
	Domestic production deduction	(1,127		)	(816		)	(601		)
	Other	(99		)	(551		)	(419		)
	Total provision for income taxes	$	17,986		$	11,050		$	10,897
	Significant components of our deferred tax assets (liabilities) are as follows:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Deferred tax assets (liabilities):
	Deferred revenue	$	12,639		$	11,074
	Stock compensation	6,287			7,447
	Inventory related items	2,713			2,947
	Tax credit carry forwards	2,168			3,160
	Reserves and accruals	327			—
	Loss carry forwards	12			64
	Other, net	—			5
	Subtotal	24,146			24,697
	Less: valuation allowance	—			(39		)
	Total net deferred tax assets	24,146			24,658
	Intangibles	(26,485		)	(26,604		)
	Depreciation and amortization	(14,331		)	(12,077		)
	Reserves and accruals	—			(353		)
	Other, net	(194		)	—
	Total deferred tax liabilities	(41,010		)	(39,034		)
	Net deferred tax liabilities	$	(16,864	)	$	(14,376	)
	Deferred income tax assets (liabilities) are provided for temporary differences that will result in future tax deductions or future taxable income, as well as the future benefit of tax credit carry forwards. We recognize deferred tax assets to the extent that we believe these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. On the basis of this evaluation, as of December 31, 2014, no valuation allowances have been recorded in any jurisdiction.
	As of December 31, 2014, we have an immaterial amount of state net operating loss carryforwards available for income tax purposes. For income tax purposes, we have California research tax credits carryforwards of $7.9 million. Federal research tax credit carryforwards from prior years have been utilized or have expired. California credits are available indefinitely to reduce cash taxes otherwise payable. Pursuant to the requirements of ASC 718, we do not include unrealized stock option attributes as components of our gross deferred tax assets. The tax-effected amounts of gross unrealized net operating loss and business tax credit carryforwards excluded under ASC 718 for the year ended December 31, 2014 are immaterial.
	In general, it is the practice and intention to reinvest the earnings of our non-U.S. subsidiaries in those operations. As of December 31, 2014, we have not made a provision for U.S. federal income and state income taxes on accumulated and current earnings of $0.8 million related to our foreign subsidiaries because these earnings are intended to be indefinitely reinvested in operations outside the United States. If we expect to distribute those earnings in the form of dividends or otherwise, we would be subject to U.S. and state income taxes reported as a component of income tax expense, in the amount of $0.3 million. This amount may be reduced by any foreign tax credits available at the time of repatriation.
	We file income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, we are subject to examination by taxing authorities, including major jurisdiction as the United States, California and United Kingdom and Germany. In 2012, we concluded audits by IRS and California Franchise Tax Board for years 2008 and 2009. However, all of the net operating loss and research credit carryforwards that may be used in future years are subject to adjustment, if and when utilized. As such our federal and California tax years remain open from 1996 and 1992, respectively. In late 2014, we were contacted by the IRS for a limited scope audit for tax years 2011 and 2012. At this time, we do not believe results of this audit will have a material impact on our financial statements.
The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, is as follows:
	(In thousands)
Year Ended December 31, 2011	$	5,796
Increases related to tax positions taken during a prior period	43
Increases related to tax positions related to MTS	1,066
Decreases related to tax positions taken during the prior period	—
Increases related to tax positions taken during the current period	422
Decreases related to settlements	(33		)
Decreases related to expiration of statute of limitations	(379		)
Year Ended December 31, 2012	$	6,915
Increases related to tax positions taken during a prior period	406
Decreases related to tax positions taken during the prior period	(79		)
Increases related to tax positions taken during the current period	764
Decreases related to settlements	—
Decreases related to expiration of statute of limitations	(32		)
Year Ended December 31, 2013	$	7,974
Increases related to tax positions taken during a prior period	63
Decreases related to tax positions taken during the prior period	(89		)
Increases related to tax positions taken during the current period	801
Decreases related to settlements	—
Decreases related to expiration of statute of limitations	(264		)
Year Ended December 31, 2014	$	8,485
As of December 31, 2014, the total amount of gross unrecognized tax benefits, if realized, would affect our tax expense by approximately $7.3 million. We recognize interest and/or penalties related to uncertain tax positions in operating expenses, which for 2014 was immaterial. We do not believe there will be any material changes in our unrecognized tax positions over the next twelve months.

Stock_Repurchases

Stock Repurchases	12 Months Ended
	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Stock Repurchases	Stock Repurchases
	The following table summarizes our stock repurchases:
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands, except per share data)
	Total number of shares repurchased	884		885		898
	Dollar amount of shares repurchased	$	24,091	$	20,962	$	12,363
	Average price paid per share	$	27.24	$	23.7	$	13.76
	In August 2012, our Board of Directors authorized a program to repurchase up to $50.0 million of common stock, of which approximately $45.1 million had been repurchased as of December 31, 2014. In November 2014, our Board of Directors authorized a program to repurchase up to $50.0 million of common stock. We expect to begin repurchasing shares under the 2014 Stock Repurchase Program upon the completion of the 2012 Stock Repurchase Program. Our stock repurchase programs have a total of $54.9 million remaining for future repurchases as of December 31, 2014, and neither program has an expiration date.

Employee_Benefits_and_ShareBas

Employee Benefits and Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation
	Stock purchase plan
	1997 Employee Stock Purchase Plan
	We have an Employee Stock Purchase Plan ("ESPP"), under which employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings; provided, however, an eligible employees' right to purchase shares of our common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
	At our 2009 Annual Meeting of Stockholders ("2009 Annual Meeting"), the stockholders approved an amendment to the ESPP, which added 2.6 million shares to the reserve for future issuance. There was a total of 0.6 million shares reserved for future issuance under the ESPP as of December 31, 2014. For the year ended December 31, 2014, 0.5 million shares of common stock were purchased under the ESPP and an aggregate of 4.7 million shares were issued under the ESPP as of December 31, 2014.
	The unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $1.8 million, and is expected to be recognized over a weighted-average period of 0.7 years as of December 31, 2014.
	Stock award plans
	2009 Equity Incentive Plan
	On May 19, 2009, at our 2009 Annual Meeting, our stockholders approved the Omnicell, Inc. 2009 Equity Incentive Plan ("2009 Plan") which authorized 2.1 million shares to be issued. The 2009 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to our employees, directors and consultants.
	The 2009 Plan succeeded the 1999 Equity Incentive Plan, the 2003 Equity Incentive Plan and the 2004 Equity Incentive Plan (collectively, the "Prior Plans"). No additional awards will be granted under any of the Prior Plans; however, all outstanding stock awards granted under the Prior Plans continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards. For purposes of determining future common shares available for grant, for each share granted as a full-value award, including restricted stock awards ("RSAs"), restricted stock unit awards ("RSUs") and performance stock awards, the shares available for issuance were reduced by 1.4 shares for each share granted. Equity awards granted as options and stock appreciation rights reduce the shares available for issuance by one share.
	On December 16, 2010, at a Special Meeting of Stockholders, our stockholders approved an amendment to increase the number of shares of common stock authorized for issuance under the 2009 Plan by 2.6 million shares and to provide that the number of common stock shares available for issuance under the 2009 Plan be reduced by 1.8 shares for each share granted as a full-value award granted on and after October 1, 2010. For each share granted as a full-value award granted prior to October 1, 2010, future shares available for grants under the 2009 Plan were reduced by 1.4 shares. Awards granted as stock options and stock appreciation rights continue to reduce the number of shares available for issuance under the 2009 Plan on a one-for-one basis. At our 2013 Annual Meeting of Stockholders, our stockholders approved an amendment to the 2009 Plan to increase the number of shares of common stock authorized for issuance by 2.5 million shares. There were 1.8 million shares of common stock reserved for future issuance under the 2009 Plan as of December 31, 2014.
	Options granted under the 2009 Plan generally become exercisable over periods of up to 4 years, generally with one-fourth of the shares vesting one year from the vesting commencement date with respect to initial grants, and the remaining shares vesting in 36 equal monthly installments thereafter; however our Board of Directors may impose different vesting terms at its discretion on any award. Options under the 2009 Plan generally expire 10 years from the date of grant. We also grant both restricted stock and restricted stock units to participants under the 2009 Plan. The Board of Directors determines the award amount, the vesting provisions and the expiration period (not to exceed ten years) for each grant. Grants of restricted stock to non-employee directors are granted on the date of our annual meeting of stockholders and vest in full on the date of our next annual meeting of stockholders, provided such non-employee director remains a director on such date. The fair value of the stock on the date of issuance is amortized to expense from the date of grant to the date of vesting. RSUs granted to employees generally vest over a period of four years and are expensed ratably on a straight-line basis over the vesting period. We consider the dilutive impact of options, restricted stock and restricted stock units in our diluted net income per share calculation.
	The 2009 Plan provides that our Board of Directors shall administer the 2009 Plan unless and until the Board of Directors delegates administration to a committee. Our Board of Directors has delegated administration of the 2009 Plan to the Compensation Committee of the Board and the 2009 Plan is generally administered by such committee. The Board of Directors may suspend or terminate the 2009 Plan at any time. The Board of Directors may also amend the 2009 Plan at any time or from time to time. However, no amendment will be effective unless approved by our stockholders after its adoption by the Board of Directors to the extent stockholder approval is necessary to satisfy the applicable listing requirements of NASDAQ.
	Performance-based restricted stock units
	In 2011, we began incorporating performance-based restricted stock units ("PSUs") as an element of our executive compensation plans. In 2012, we granted 125,000 PSUs to our executive officers, of which 62,500 PSUs became eligible for vesting upon the achievement of a certain level of shareholder return for 2012. In 2013, we granted 137,500 PSUs to our executive officers all of which became eligible for vesting upon the achievement of a certain level of shareholder return for the period from January 1, 2013 through February 28, 2014. In 2014, we granted 132,500 PSUs to our executive officers, all, none or a portion of which may become eligible for vesting depending on the level of shareholder return for 2014 and eligible for further time-based vesting based on the ranking of our total shareholder return.
	The fair value of a PSU award is the average of trial-specific values of the award over each of one million Monte Carlo trials. Each trial-specific value is the market value of the award at the end of the one-year performance period discounted back to the grant date. The market value of the award for each trial at the end of the performance period is the product of (a) the per share value of Omnicell stock at the end of the performance period and (b) the number of shares that vest. The number of shares that vest at the end of the performance period depends on the percentile ranking of the total shareholder return for Omnicell stock over the performance period relative to the total shareholder return of each of the other companies in the NASDAQ Healthcare Index (the "Index").
	Vesting for the PSUs is based both on the percentile placement of our total stockholder return among the companies listed in the Index and time-based vesting. We calculate total stockholder return based on the one year annualized rates of return reflecting price appreciation plus reinvestment of dividends. For PSUs granted on February 4, 2014, stock price appreciation is calculated based on the trailing 20-day average stock price from the first trading day of March 2014, compared to the trailing 20-day average stock price from the first trading day of March 2015. For PSUs granted in 2013, stock price appreciation is calculated based on the average closing prices of the applicable company’s common stock for the 20 trading days ended on the last trading day of 2012 as compared to the average closing prices of the common stock for the 20 trading days preceding the first trading day of March 2014. For PSUs granted in 2012, stock price appreciation is calculated based on the average closing prices of the applicable company's common stock for the 20 trading days ending on the last trading day of 2011 as compared to the average closing prices for the 20 trading days ended on the last trading day of 2012.
	On January 17, 2012, the Compensation Committee confirmed 76.3% as the percentile rank of our 2011 total stockholder return. This resulted in 120% of the 2011 PSUs, or 120,000 shares, becoming eligible for further time-based vesting. The eligible PSUs vest as follows: 25% of the eligible awards for the first year vested on January 17, 2012 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three-year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 120,000 shares eligible for time-based vesting under the 2011 PSUs, 30,000 shares vested during the year ended December 31, 2014.
	On January 22, 2013, the Compensation Committee confirmed 35.3% as the percentile rank of our 2012 total stockholder return. This resulted in 50% of the 2012 PSUs, or 62,500 shares, as eligible for further time-based vesting. The eligible PSUs vest as follows: 25% of the eligible shares vested immediately on January 22, 2013 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three-year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 62,500 shares eligible for time-based vesting under the 2012 PSUs, 15,600 shares vested during the year ended December 31, 2014.
	On March 20, 2014, the Compensation Committee confirmed 63.9% as the percentile rank of our 2013 total stockholder return. This resulted in 100% of the 2013 PSUs, or 137,500 shares, as eligible for further time-based vesting. The eligible performance based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on March 20, 2014 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three-year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service. Of the 137,500 shares eligible for time-based vesting under the 2013 PSUs, 68,750 shares vested during the year ended December 31, 2014.
	On February 5, 2014, the Compensation Committee approved PSUs of 132,500 shares. If the minimum performance threshold is met as determined by the Compensation Committee in 2015, the eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares will vest immediately, with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	Valuation of share-based awards
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The fair value of shares issued under the employee stock purchase plans is estimated on the date of issuance using the Black-Scholes-Merton model.
	The following assumptions were used to estimate the fair value of share-based awards:
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Stock Option Plans
	Risk-free interest rate (1)	1.6	%	1.2	%		0.9	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	34.9	%	43.1	%		45.8	%
	Expected life (3)	4.8 years		5.3 years			5.2 years
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Employee Stock Purchase Plan
	Risk-free interest rate (1)	0.2	%	0.2	%		0.2	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	33.2	%	35.1	%		38.5	%
	Expected life (3)	0.5 - 2 years		0.5 - 2 years			0.5 - 2 years
	_________________________________________________
	(1)	The risk-free interest rate for both stock options and the ESPP is based on the zero-coupon U.S. Treasury rate curve in effect at the time of the option grant or at the beginning of the ESPP offering period.
	(2)	Expected volatility for both stock options and the ESPP reflects a combination of historical and market-based implied volatility consistent with ASC 718 and SEC Staff Accounting Bulletin 107. We determined that the combination of historical and market-based implied volatility provides a more accurate reflection of our market conditions and is more representative of future stock price trends than employing solely historical volatility.
	(3)	Represents the period of time that options granted are expected to be outstanding, which is derived from historical data on employee exercise and post-vesting employment termination behavior.
	Share-based compensation expense
	We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimate grant date fair value method of accounting in accordance with ASC 718, Stock Compensation. We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued using the Monte Carlo simulation model.
	The following table sets forth the total share-based compensation expense recognized in our Consolidated Statements of Income:
		Year Ended
		December 31,			December 31,				December 31,
		2014			2013				2012
		(In thousands)
	Cost of product and service revenues	$	1,456		$	1,241			$	1,011
	Research and development	1,655			1,359				889
	Selling, general and administrative	9,674			8,551				7,314
	Total share-based compensation expense	$	12,785		$	11,151			$	9,214
	We did not capitalize any share-based compensation as inventory as such amounts were not material for the years ended December 31, 2014, December 31, 2013 and December 31, 2012. Income tax benefits realized from share-based compensation were $4.5 million, $2.4 million and $2.6 million, for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively.
	Stock options activity
	A summary of the stock option activity under the 2009 Plan is presented below:
		Number of		Weighted-Average				Weighted-Average		Aggregate
		Shares		Exercise Price				Remaining Years		Intrinsic Value(1)
		(In thousands, except per share data)
	Outstanding at December 31, 2013	3,143		$	15.82			5.6
	Granted	641		28.11
	Exercised	(1,007	)	14.74
Expired	(12	)	19.88
Forfeited	(93	)	19.97
Outstanding at December 31, 2014	2,672		$	19.02			6.5		$	37,692
Exercisable at December 31, 2014	1,514		$	15.66			4.7		$	26,447
Vested and expected to vest at December 31, 2014	2,640		$	18.92			6.4		$	37,481
_________________________________________________
(1)	Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the year as reported by the NASDAQ Global Select Market, and the exercise price of the option.
The weighted-average fair value per share of options granted during 2014, 2013 and 2012 was $9.12, $8.09 and $6.13, respectively. The intrinsic value of options exercised during 2014, 2013 and 2012 was $14.1 million, $14.0 million and $2.8 million, respectively.
As of December 31, 2014, total unrecognized compensation cost related to unvested stock options was $8.8 million, which is expected to be recognized over a weighted-average vesting period of 2.8 years.
Restricted stock activity
A summary of the restricted stock activity under the 2009 Plan is presented below:
	Number of		Weighted-Average				Weighted-Average		Aggregate
	Shares		Grant Date Fair Value				Remaining Years		Intrinsic Value
	(In thousands, except per share data)
Restricted Stock Units
Outstanding at December 31, 2013	362		$	17.15			2.5
Granted	238		28.88
Vested	(181	)	17.51
Forfeited	(20	)	16.5
Outstanding and unvested at December 31, 2014	399		$	24			1.5		$	13,190
Expected to vest at December 31, 2014	387						1.5		$	12,807
The weighted-average grant date fair value per share of RSUs granted during 2014, 2013 and 2012 was $28.88, $19.87 and $14.58, respectively. The total fair value of RSUs that vested in 2014, 2013 and 2012 was $3.2 million, $4.4 million and $2.3 million, respectively.
As of December 31, 2014, total unrecognized compensation cost related to RSUs was $8.7 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.6 years.
	Number of		Weighted-Average
	Shares		Grant Date Fair Value
	(In thousands, except per share data)
Restricted Stock Awards
Outstanding at December 31, 2013	52		$	18.43
Granted	38		26.42
Vested	(54	)	18.68
Forfeited	—		—
Outstanding and unvested at December 31, 2014	36		$	26.47
The weighted-average grant date fair value per share of RSAs granted during 2014, 2013 and 2012 was $26.42, $18.20 and $14.19, respectively. The total fair value of RSAs that vested in 2014, 2013 and 2012 was $1.0 million, $1.1 million and $1.1 million, respectively.
As of December 31, 2014, total unrecognized compensation cost related to RSAs was $0.4 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.5 years.
Performance-based restricted stock units activity
A summary of the performance-based restricted stock activity under the 2009 Plan is presented below:
	Number of		Weighted-Average
	Shares		Grant Date Fair Value Per Unit
	(In thousands, except per share data)
Unvested at December 31, 2013	225		$	13.32
Granted	158		20.94
Vested	(114	)	13.32
Cancelled	(36	)	16.73
Unvested at December 31, 2014	233		$	17.96
The weighted-average grant date fair value per share of PSUs granted during 2014, 2013 and 2012 was $20.94, $14.68 and $10.94, respectively. The total fair value of PSUs that vested in 2014, 2013 and 2012 was $1.5 million, $0.7 million and $0.7 million, respectively.
As of December 31, 2014, total unrecognized compensation cost related to PSUs was approximately $2.0 million, which is expected to be recognized over the remaining weighted-average period of 1.2 years.
401(k) Plan
We have established a 401(k) tax-deferred savings plan ("Omnicell Plan"), whereby eligible employees may contribute a percentage of their eligible compensation, but not greater than 75% of their earnings, up to the maximum as required by law. On January 1, 2009, we began matching 401(k) contributions, up to a maximum of 3% of employee contributions, not to exceed $1,000 for the year. In the first quarter of 2013, the MTS 401(k) tax-deferred savings plan was merged with the Omnicell Plan. On January 1, 2014, the Omnicell Plan was changed to match 50% of employee contributions up to $1,500, with no limit to employee contributions as long as such contributions do not exceed 75% of their earnings. Effective January 1, 2015, we will begin to match 50% of employee contributions up to $2,000, with the same limitations on employee contributions as of January 1, 2014.
Our contributions under the Omnicell Plan were $1.3 million, $1.1 million and $0.8 million in 2014, 2013 and 2012, respectively.
Preferred Stock
There were 5.0 million preferred shares authorized, and no preferred shares issued or outstanding as of December 31, 2014 and December 31, 2013.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information	Segment Information
	In the first quarter of 2014, we began to manage our business according to two product segments because many of our Acute Care and Non-Acute Care customers were converging to provide services across the continuum of care. We modified our segment reporting structure to match our operating structure based on how our CODM views the business and allocates resources. The two operating segments, which are the same as our reporting segments, are as follows:
	Automation and Analytics
	The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. Our Automation and Analytics products are designed to enable our customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, our systems can be tailored to specific customer needs.
	Medication Adherence
	The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. These products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name of MTS, Surgichem, and under the Omnicell brand, and dispensing systems sold under the Omnicell brand. MTS products consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities.
	The historical information presented has been retrospectively adjusted to reflect the new segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations. Except for goodwill, as discussed in Note 8, our assets are not discretely identified or allocated by segment.
	The following table summarizes the financial performance of our reporting segments:
		Year Ended
		December 31, 2014						December 31, 2013						31-Dec-12
		Automation and		Medication		Total		Automation and		Medication		Total		Automation and		Medication		Total
		Analytics		Adherence (1)				Analytics		Adherence				Analytics		Adherence (2)
		(In thousands)
	Revenues	$	354,095	$	86,805	$	440,900	$	302,917	$	77,668	$	380,585	$	260,160	$	53,867	$	314,027
	Cost of revenues	151,327		55,713		207,040		129,314		47,872		177,186		111,599		31,840		143,439
	Gross profit	202,768		31,092		233,860		173,603		29,796		203,399		148,561		22,027		170,588
	Operating expenses	155,156		29,121		184,277		140,087		28,013		168,100		127,467		15,995		143,462
	Income from operations	$	47,612	$	1,971	$	49,583	$	33,516	$	1,783	$	35,299	$	21,094	$	6,032	$	27,126
	_________________________________________________
	(1)	Includes Surgichem results as of August 2014.
	(2)	Includes MTS results as of May 2012.
	Geographical Information
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands)
	United States	$	394,234	$	334,412	$	287,716
	Foreign countries (1)	46,666		46,173		26,311
	Total revenues	$	440,900	$	380,585	$	314,027
	_________________________________________________
	(1)	No individual country represented more than 10% of the respective totals.
	Significant customers
	There were no significant customers that accounted for more than 10% of our total revenues in 2014, 2013 and 2012.

Credit_Agreement

Credit Agreement	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Credit Agreement	Credit Agreement
	In September 2013, we entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. The Credit Agreement provides for a $75 million revolving credit facility with a $10 million letter of credit sub-limit. Loans under the Credit Agreement mature on September 25, 2018. The Credit Agreement permits us to request one or more increases in the aggregate commitments provided that such increases do not exceed $25 million in the aggregate. We expect to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. Our obligations under the Credit Agreement are guaranteed by certain of our domestic subsidiaries and secured by substantially all of our and the subsidiary guarantors’ assets. We have not yet drawn any funds under the credit facility to date.
	Amounts drawn under the Credit Agreement bear interest, at our election, at a Eurodollar rate plus a margin of 1.75% per annum, or an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.75%. We are required to pay a commitment fee of 0.25% per annum on the aggregate undrawn amount of the commitments under the credit facility.
	On November 5, 2014, we entered into Amendment Number One (“Amendment”) to the Credit Agreement. The Amendment increases the amount of our common stock that may be repurchased by us in open market transactions authorized by our Board of Directors, together with any repurchases of our common stock from any consultants, employees, officers or directors of the Company or any of our subsidiaries following the death, disability, retirement or termination of employment of such employees, officers or directors, from $25 million to $50 million per year.
	The Credit Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require us to, among other things, maintain a maximum consolidated total leverage ratio and a minimum consolidated fixed charge coverage ratio, in each case, as of the last day of each quarter. We were in full compliance with all covenants as of December 31, 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	On February 26, 2015, Omnicell International, Inc., a wholly-owned subsidiary of Omnicell, Inc. entered into an agreement with Apotheka Imedisa 2001 S.A., Holger Wallat, Dirk Rolf Beils and Peter Jansen (collectively, the “Selling Shareholders”) for the purchase of the entire registered share capital of Mach 4 Automatisierungstechnik GmbH (“Mach4”) (the “Share Purchase Agreement”). Mach4 is a provider of automated medication management systems to retail and hospital pharmacy customers primarily in Europe, with additional installations in China, the Middle East and Latin America. The contemplated total aggregate consideration is $18.0 million in cash, minus existing debt and subject to certain adjustments provided for in the Share Purchase Agreement. The closing of the acquisition is subject to certain closing conditions.
	On February 27, 2015, the Company received a notice from an Omnicell employee alleging, among other matters, the existence of a "side letter" arrangement with an Omnicell customer for certain discounts and Omnicell products that were to be provided at no cost, but which were not reflected in the final invoices paid by the customer. Following the receipt of this notice, the Company commenced an internal investigation into these allegations. This investigation was concluded on March 25, 2015. Based on the results of the investigation, the Company has determined that effective internal control over financial reporting was maintained in all material respects and that there are no changes required to be made to the Company’s Consolidated Financial Statements.
	On March 19, 2015, a putative class action lawsuit was filed against the Company and two executive officers in the U.S. District Court for the Northern District of California, captioned Nelson v. Omnicell, Inc., et al., Case No. 3:15-cv-01280-HSG. The complaint purports to assert claims on behalf of a class of purchasers of the Company’s stock between May 2, 2014 and March 2, 2015. It alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by purportedly making false and misleading statements regarding the existence of a “side letter” arrangement and the adequacy of internal controls that allegedly resulted in false and misleading financial statements. The Company and the individual defendants have not yet been served with the Complaint. The Company believes that the claims have no merit and will defend the lawsuit vigorously.

Schedule_II_Valuation_and_Qual

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
				Additions
		Balance at		Charged to		Credited to			Amount			Balance at
		Beginning of Period (1)		Costs and Expenses (2)		Other Accounts (3)			Written Off (4)			End of Period (1)
		(In thousands)
	Year ended December 31, 2012
	Accounts receivable	$	443	$	316	$	(57	)	$	20		$	722
	Investment in sales-type leases	284		425		—			(102		)	607
	Total allowances deducted from assets	$	727	$	741	$	(57	)	$	(82	)	$	1,329
	Year ended December 31, 2013
	Accounts receivable	$	722	$	195	$	(67	)	$	(360	)	$	490
	Investment in sales-type leases	607		49		—			(489		)	167
	Total allowances deducted from assets	$	1,329	$	244	$	(67	)	$	(849	)	$	657
	Year ended December 31, 2014
	Accounts receivable	$	490	$	941	$	(60	)	$	(165	)	$	1,206
	Investment in sales-type leases	167		—		(5		)	—			162
	Total allowances deducted from assets	$	657	$	941	$	(65	)	$	(165	)	$	1,368
	__________________________________________________
	(1)	Allowance for doubtful accounts.
	(2)	Represents amounts charged to bad debt expense.
	(3)	Represents amounts credited to bad debt expense.
	(4)	Represents amounts written-off, net of recoveries.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation
	The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's consolidated financial position, results of operations and cash flows for the periods presented. The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The results of companies acquired during the year are included in the Consolidated Financial Statements from the effective date of acquisition.
Use of estimates	Use of estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes.
Foreign currency translation	Foreign currency forward contracts. We enter into foreign currency forward contracts to protect our business from the risk that exchange rates may affect the eventual cash flows resulting from intercompany transactions between Omnicell and our foreign subsidiaries. These transactions primarily arise as a result of products manufactured in the United States and sold to foreign subsidiaries in U.S. dollars rather than the subsidiaries' functional currencies. These forward contracts are considered to be financial derivative instruments and are recorded at fair value. Changes in fair values of these financial derivative instruments are either recognized in other comprehensive income or net income depending on whether the derivative has been designated and qualifies as a hedging instrument. We had no foreign currency forward contracts which qualify for hedge accounting as of December 31, 2014 and December 31, 2013, and had no foreign currency forward contracts as of December 31, 2014.
	Foreign currency translation
	We translate the assets and liabilities of our non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recorded as foreign currency translation adjustments and included in accumulated other comprehensive income in stockholders’ equity.
Revenue Recognition	Revenue recognition
	We earn revenues from sales of our medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. Revenues related to consumable products are reported net of discounts provided to our customers. Our customer arrangements typically include one or more of the following deliverables:
	Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.
	Software. Additional software applications that enable incremental functionality of our equipment.
	Installation. Installation of equipment as integrated systems at customers' sites.
	Post-installation technical support. Phone support, on-site service, parts and access to unspecified software upgrades and enhancements, if and when available.
	Professional services. Other customer services, such as training and consulting.
	We recognize revenue when the earnings process is complete, based upon our evaluation of whether the following four criteria have been met:
	Persuasive evidence of an arrangement exists. We use signed customer contracts and signed customer purchase orders as evidence of an arrangement for leases and sales. For service engagements, we use a signed services agreement and a statement of work to evidence an arrangement.
	Delivery has occurred. Equipment and embedded software product delivery is deemed to occur upon successful installation and receipt of a signed and dated customer confirmation of installation letter, providing evidence that we have delivered what a customer ordered. In instances of a customer self-installation, product delivery is deemed to have occurred upon receipt of a signed and dated customer confirmation letter. If a sale does not require installation, we recognize revenue on delivery of products to the customer, including transfer of title and risk of loss, assuming all other revenue criteria are met. For existing distributors, where installation of equipment training has been previously provided and the distributor is certified to install our equipment at the end-user customer facility, we recognize revenue from sales of products to the distributor upon shipment assuming all other revenue criteria are met since we do not allow for rights of return or refund. For new distributors, where we have not provided installation of equipment training, revenue on the sales of products to the distributor is deferred until the distributor has completed the Distributor Training Program and has been certified to install our equipment at the end-user facility. For the sale of consumable blister cards, we recognize revenue when title and risk of loss of the products shipped have transferred to the customer, which usually occurs upon shipment from our facilities. Assuming all other revenue criteria are met, we recognize revenue for support services ratably over the related support services contract period. We recognize revenue on training and professional services as they are performed.
	Fee is fixed or determinable. We assess whether a fee is fixed or determinable at the outset of the arrangement based on the payment terms associated with the transaction. We have established a history of collecting under the original contract without providing concessions on payments, products or services.
	Collection is probable. We assess the probability of collecting from each customer at the outset of the arrangement based on a number of factors, including the customer's payment history and its current creditworthiness. If, in our judgment, collection of a fee is not probable, we defer the revenue until the uncertainty is removed, which generally means revenue is recognized upon our receipt of cash payment assuming all other revenue criteria are met. Our historical experience has been that collection from our customers is generally probable.
	In arrangements with multiple deliverables, assuming all other revenue criteria are met, we recognize revenue for individual delivered items if they have value to the customer on a standalone basis. We allocate arrangement consideration at the inception of the arrangement to all deliverables using the relative selling price method. This method requires us to determine the selling price at which each deliverable could be sold if it were sold regularly on a standalone basis. When available, we use vendor-specific objective evidence ("VSOE") of the selling price. VSOE represents the price charged for a deliverable when it is sold separately, or for a deliverable not yet being sold separately, the price established by management with the relevant authority. We consider VSOE to exist when approximately 80% or more of our standalone sales of an item are priced within a reasonably narrow pricing range (plus or minus 15% of the median rates). We have established VSOE of the selling price for our post-installation technical support services and professional services. When VSOE of selling price is not available, third-party evidence ("TPE") of selling price for similar products and services is acceptable; however, our offerings and market strategy differ from those of our competitors, such that we cannot obtain sufficient comparable information about third parties' prices. If neither VSOE nor TPE are available, we use our best estimates of selling prices ("BESP"). We determine BESP considering factors such as market conditions, sales channels, internal costs and product margin objectives and pricing practices. We regularly review and update our VSOE and BESP information.
	The relative selling price method allocates total arrangement consideration proportionally to each deliverable on the basis of its estimated selling price. In addition, the amount recognized for any delivered items cannot exceed that which is not contingent upon delivery of any remaining items in the arrangement.
	We also use the residual method to allocate revenue between the software products that enable incremental equipment functionality, and thus are not deemed to deliver its essential functionality, and the related post-installation technical support, as these products and services continue to be accounted for under software revenue recognition rules. Under the residual method, the amount allocated to the undelivered elements equals VSOE of fair value of these elements. Any remaining amounts are attributed to the delivered items and are recognized when those items are delivered.
	A portion of our sales are made through multi-year lease agreements. Under sales-type leases, we recognize revenue for our hardware and software products net of lease execution costs such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once our installation obligations have been met. We optimize cash flows by selling a majority of our non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. We have no obligation to the leasing company once the lease has been sold. Some of our sales-type leases, mostly those relating to U.S. government hospitals, are retained in-house. Interest income in these leases is recognized in product revenue using the effective interest method.
Cash equivalents	Cash equivalents. We classify investments as cash equivalents if their original or remaining contractual maturity is three months or less at the date of purchase. Cash equivalents are carried at amounts that approximate fair value due to the short period of time to maturity. Our cash equivalents are maintained in demand deposit accounts with financial institutions of high credit quality, and are invested in institutional money market funds, short-term bank time deposits and similar short duration instruments with fixed maturities. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest. We have not experienced any credit losses from our cash investments.
Marketable securities	Marketable securities. Our marketable securities and investments are classified as available-for-sale, and unrealized gains and losses, net of tax, are included in accumulated other comprehensive income.
Equity investments	Equity investments. We make equity investments in privately-held companies whose businesses are complementary to our business. The investment in which we hold less than 20% of the voting stock outstanding and do not exert significant influence is accounted for under the cost method of accounting. The cost amount of this investment was $0.4 million as of December 31, 2014 and December 31, 2013, and was no longer realizable as of December 31, 2014 and therefore considered impaired as discussed in Note 9, Other Assets. We invested $0.9 million to purchase 15% of our United Kingdom automation and analytics products distributor’s outstanding equity. We record this investment under the equity method of accounting as we have the right to appoint a member to this company's board of directors as well as certain other voting rights and, therefore, we believe we have the ability to exert significant influence over this distributor's operations. Our proportionate equity share of the income of this distributor, recognized in interest and other income, net was immaterial for the years ended December 31, 2014, December 31, 2013 and December 31, 2012. Our equity investments are included in other long-term assets. We assess the recoverability of these investments by reviewing various indicators for other-than-temporary impairment.
Debt	Debt. Our debt includes a $75 million revolving credit facility. Borrowings under our revolving credit facility would be recognized at cost plus accrued interest based upon stated interest rates. We have not yet drawn any funds under the credit facility to date.
Accounts receivable and notes receivable (net investment in sale-type leases)	Accounts receivable and notes receivable (net investment in sales-type leases)
	We actively manage our accounts receivable to minimize credit risk. We typically sell to customers for which there is a history of successful collection. New customers are subject to a credit review process, which evaluates that customer's financial position and ability to pay. We continually monitor and evaluate the collectability of our trade receivables based on a combination of factors. We record specific allowances for doubtful accounts when we become aware of a specific customer's impaired ability to meet its financial obligation to us, such as in the case of bankruptcy filings or deterioration of financial position. There were no significant customers that accounted for more than 10% of our accounts receivable as of December 31, 2014 and December 31, 2013.
	Uncollectible amounts are charged off against trade receivables and the allowance for doubtful accounts when we make a final determination that there is no reasonable expectation of recovery. Estimates are used in determining our allowances for all other customers based on factors such as current trends, the length of time the receivables are past due and historical collection experience. While we believe that our allowance for doubtful accounts receivable is adequate and that the judgment applied is appropriate, such estimated amounts could differ materially from what will actually be uncollectible in the future.
	The retained in-house leases discussed above are considered financing receivables. Our credit policies and evaluation of credit risk and write-off policies are applied alike to trade receivables and the net investment in sales-type leases. For both, an account is generally past due after thirty days. The financing receivables also have customer-specific reserves for accounts identified for specific impairment and a non-specific reserve applied to the remaining population, based on factors such as current trends, the length of time the receivables are past due and historical collection experience. The retained in-house leases are not stratified by portfolio or class. Financing receivables which are reserved are generally transferred to cash-basis accounting so that revenue is recognized only as cash is received. However, the cash basis accounts continue to accrue interest.
Sales of accounts receivable	Sales of accounts receivable
	We record the sale of our accounts receivables as "true sales" in accordance with accounting guidance for transfers and servicing of financial assets.
Inventory	Inventory
	Inventories are stated at the lower of cost (utilizing standard costs, applying the first-in, first-out method) or market. Cost elements included in inventory are direct labor and materials plus applied overhead. We routinely assess on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. We write down our inventory for estimated obsolescence, excess or unmarketable quantities equal to the difference between the cost of the inventory and its estimated market value based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than we projected, additional inventory write-downs may be required.
Property and Equipment	Property and equipment
	Property and equipment less accumulated depreciation are stated at historical cost. Our expenditures for property and equipment are for computer equipment and software used in the administration of our business, and for leasehold improvements to our leased facilities. We also develop molds and dies used in long-term manufacturing arrangements with suppliers and for production automation equipment used in the manufacturing of consumable blister card components. Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 - 7 years
	Equipment	3 - 12 years
	We capitalize costs related to computer software developed or obtained for internal use in accordance with ASC 350-40, Internal-Use Software. Software obtained for internal use has generally been enterprise-level business and finance software that we customize to meet our specific operational needs. Costs incurred in the application development phase are capitalized and amortized over their useful lives, which is generally five years. Costs recognized in the preliminary project phase and the post-implementation phase are expensed as incurred.
Software development costs	Software development costs
	We capitalize software development costs in accordance with ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed, under which certain software development costs incurred subsequent to the establishment of technological feasibility may be capitalized and amortized over the estimated lives of the related products. We establish feasibility when we complete a working model and amortize development costs over the estimated lives of the related products ranging from three to five years. We capitalized software development costs of $10.4 million and $7.8 million which are included in other assets as of December 31, 2014 and December 31, 2013, respectively. We recorded $4.4 million, $3.2 million and $2.3 million to cost of revenues for amortization of capitalized software development costs for the years ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively. All development costs prior to the completion of a working model are recognized as research and development expense.
Business combinations	Business Combinations
	We use the acquisition method of accounting under the authoritative guidance on business combinations. Each acquired company’s operating results are included in our Consolidated Financial Statements starting on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired and liabilities assumed as of the date of acquisition are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.
	Amounts allocated to assets and liabilities are based upon fair values. Such valuations require management to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. These estimates are based on historical experience and information obtained from the management of the acquired companies and the estimates are inherently uncertain. The separately identifiable intangible assets generally include customer relationships, technology, and trade names.
Goodwill and intangible assets	Goodwill and intangible assets
	Goodwill. We review goodwill for impairment on an annual basis on the first day of the fourth quarter of each year at the reporting unit level. Our reporting units are the same as our operating segments, which are Automation and Analytics and Medication Adherence. A qualitative assessment is initially made to determine whether it is necessary to perform quantitative testing. This initial assessment includes, among others, consideration of: (i) past, current and projected future earnings and equity; (ii) recent trends and market conditions; and (iii) valuation metrics involving similar companies that are publicly-traded and acquisitions of similar companies, if available. If this initial qualitative assessment indicates that it is more likely than not that impairment exists, or if we decide to bypass this option, we proceed to a two-step impairment test. The first step ("Step 1") involves a comparison between the estimated fair values of our reporting units with their respective carrying amounts including goodwill. The methods for estimating reporting unit values include asset and liability fair values and other valuation techniques, such as discounted cash flows and multiples of earnings or revenues. If the carrying value exceeds estimated fair value, there is an indication of potential impairment, and the second step is performed to measure the amount of impairment. The second step involves calculating an implied fair value of goodwill by measuring the excess of the estimated fair value of the reporting units over the aggregate estimated fair values of the individual assets less liabilities. If the carrying value of goodwill exceeds the implied fair value of goodwill, an impairment charge is recorded for the excess.
	To determine each reporting units’ fair value in the second step, we would use the income approach which is based on the estimated discounted future cash flows of that reporting unit. The estimated fair value of each reporting unit under the income approach is corroborated with the market approach, which measures the value of a business through an analysis of recent sales or offerings of a comparable entity. We also consider our market capitalization on the date of the analysis to ensure the reasonableness of the sum of our reporting units’ estimated fair value.
	Intangible assets. In connection with our acquisitions, we generally recognize assets for customer relationships, technology and trade names. Intangible assets are carried at cost less accumulated amortization. Such amortization is provided on a straight-line basis or on an accelerated basis based on a pattern of economic benefit that is expected to be obtained over the estimated useful lives of the respective assets, generally from 1 to 30 years. Amortization for technology is recognized in cost of product revenues, and amortization for customer relationships and trade names is recognized in selling, general and administrative expenses.
	We assess the impairment of identifiable intangible assets whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Recoverability of an asset is measured by the comparison of the carrying amount to the sum of the undiscounted estimated future cash flows the asset is expected to generate, offset by estimated future costs to dispose of the product to which the asset relates. If an asset is considered to be impaired, the amount of such impairment would be measured as the difference between the carrying amount of the asset and its fair value. Our cash flow assumptions are based on historical and forecasted future revenue, operating costs, and other relevant factors. Assumptions and estimates about the remaining useful lives of our intangible assets are subjective and are affected by changes to our business strategies. If management’s estimates of future operating results change, or if there are changes to other assumptions, the estimate of the fair value of our assets could change significantly. Such change could result in impairment charges in future periods, which could have a significant impact on our operating results and financial condition.
Valuation of share-based awards	Valuation of share-based awards
	We account for share-based compensation in accordance with ASC 718, Stock Compensation ("ASC 718"). We recognize compensation expense related to stock-based compensation, including the awarding of employee stock awards and restricted stock units, based on the grant date estimated fair value. We amortize the fair value of the employee stock awards on a straight-line basis over the requisite service period of the award, which is generally the vesting period. We estimate the fair value of stock-based compensation awards using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price, and closing price of our common stock on the date of grant. The expected volatility is based on a combination of historical and market-based implied volatility, and the expected life of the awards is based on our historical experience of employee stock option exercises, including forfeitures. The valuation assumptions we use in estimating the fair value of employee share-based awards may change in future periods. We calculate our pool of excess tax benefits available within additional paid-in capital in accordance with the provisions of ASC 718.
Accounting for income tax	Accounting for income taxes
	We record an income tax provision for the anticipated tax consequences of the reported results of operations. In accordance with U.S. GAAP, the provision for income taxes is computed using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the periods in which those tax assets and liabilities are expected to be realized or settled. In the event that these tax rates change, we will incur a benefit or detriment on our income tax expense in the period of change. If we were to determine that all or part of the net deferred tax assets are not realizable in the future, we will record a valuation allowance that would be charged to earnings in the period such determination is made.
	In accordance with ASC 740, Income Taxes, we recognize the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of U.S. GAAP and complex tax laws. Resolution of these uncertainties in a manner inconsistent with management’s expectations could have a material impact on our financial condition and operating results.
Deferred service revenue and deferred gross profit	Deferred service revenue and deferred gross profit
	Deferred service revenue and deferred gross profit arise when customers have been billed and/or have received products and/or services in advance of revenue recognition. Our deferred gross profit, classified as a current liability, consists primarily of unearned revenue on sale of equipment for which installation has not been completed, net of deferred cost of sales for such equipment and the unearned revenue for software licenses. Our deferred service revenue, separated into current and long-term liabilities, consists of the unearned portion of service contracts for which revenue is recognized over their duration.
Commissions	Commissions
	Sales commissions are incremental and directly related to customer sales contracts in which revenue is deferred. These commission costs are accrued and recorded in prepaid expenses upon execution of a non-cancelable customer contract and subsequently expensed in the period of revenue recognition.
Shipping costs	Shipping costs
	Outbound freight billed to customers is recorded as product revenue. The related shipping and handling costs are expensed as part of selling, general and administrative expense.
Recently adopted accounting standards and recently issued authoritative guidance	Recently adopted accounting standards
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Income Taxes: Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.
	Recently issued authoritative guidance
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, that requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers, and will replace most existing revenue recognition guidance in U.S. GAAP. The new standard is effective for us in the first quarter of 2017, and early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that the standard will have on our Consolidated Financial Statements and related disclosures.
	There was no other recently issued authoritative guidance that has a material impact on our Consolidated Financial Statements through the reporting date.
Guarantees	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of December 31, 2014 and December 31, 2013.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property and Equipment	Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 - 7 years
	Equipment	3 - 12 years
	Property and equipment consist of the following assets:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Equipment	$	42,829		$	40,180
	Furniture and fixtures	5,689			5,260
	Leasehold improvements	8,701			7,394
	Purchased software	28,920			20,199
	Construction in progress	1,538			2,649
		87,677			75,682
	Accumulated depreciation and amortization	(51,499		)	(40,428		)
	Total property and equipment, net	$	36,178		$	35,254

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
Business Acquisition [Line Items]
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following represents the details of the acquired intangible assets:
		Intangible Assets			Useful Life
		Acquired			(Years)
		(In thousands, except for years)
	Trade name	$	6,800		12
	Customer relationships	50,500			28 to 30
	Acquired technology	26,600			20
	Intangibles acquired	$	83,900
Surgichem [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the purchase price allocation included in our Consolidated Balance Sheets:
		(In thousands)
	Cash	$	153
	Accounts receivable	2,462
	Inventory	2,190
	Deferred tax assets and other current assets	361
	Total current assets	$	5,166
	Property and equipment	164
	Intangibles	5,730
	Goodwill	12,112
	Total assets	$	23,172
	Current liabilities	1,191
	Long-term deferred tax liabilities	1,104
	Total purchase price	$	20,877
MedPak Holdings, Inc. [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the purchase price allocation included in our Consolidated Balance Sheets:
		(In thousands)
	Cash	$	2,000
	Accounts receivable	7,403
	Inventory	11,726
	Deferred tax assets and other current assets	2,894
	Total current assets	$	24,023
	Property and equipment	9,807
	Intangible assets	83,900
	Goodwill	82,800
	Other long-term assets	308
	Total assets	$	200,838
	Current liabilities	(7,917		)
	Long-term deferred tax liabilities	(33,386		)
	Other long-term liabilities	(1,223		)
	Total purchase price	$	158,312

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The calculation of basic and diluted net income per share is as follows:
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands, except per share data)
	Net income	$	30,518	$	23,979	$	16,178
	Weighted-average shares outstanding — basic	35,650		34,736		33,307
	Add: Dilutive effect of employee stock plans	972		1,041		906
	Weighted-average shares outstanding — diluted	36,622		35,777		34,213
	Net income per share — basic	$	0.86	$	0.69	$	0.49
	Net income per share — diluted	$	0.83	$	0.67	$	0.47
	Anti-dilutive weighted-average shares related to stock award plans	640		850		2,149

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value On A Recurring Basis	The following table summarizes our assets measured at fair value on a recurring basis using Level 1 inputs within the fair value hierarchy:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Cash	$	61,311	$	38,823
	Cash equivalents	64,577		65,708
	Total cash and cash equivalents	$	125,888	$	104,531

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory	Inventories consist of the following components:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Raw materials	$	8,254	$	10,765
	Work in process	64		534
	Finished goods	23,236		20,158
	Total inventories, net	$	31,554	$	31,457

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Depreciation and amortization of property and equipment are provided over their estimated useful lives, using the straight-line method, as follows:
	Computer equipment and related software	3 - 5 years
	Leasehold and building improvements	Shorter of the lease term or the estimated useful life
	Furniture and fixtures	5 - 7 years
	Equipment	3 - 12 years
	Property and equipment consist of the following assets:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Equipment	$	42,829		$	40,180
	Furniture and fixtures	5,689			5,260
	Leasehold improvements	8,701			7,394
	Purchased software	28,920			20,199
	Construction in progress	1,538			2,649
		87,677			75,682
	Accumulated depreciation and amortization	(51,499		)	(40,428		)
	Total property and equipment, net	$	36,178		$	35,254

Net_Investment_in_SalesType_Le1

Net Investment in Sales-Type Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	Net investment in sales-type leases consist of the following components:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Net minimum lease payments to be received	$	17,616		$	18,172
	Less: unearned interest income portion	(1,131		)	(1,455		)
	Net investment in sales-type leases	16,485			16,717
	Less: short-term portion	(5,637		)	(5,232		)
	Long-term net investment in sales-type leases	$	10,848		$	11,485
Schedule of Net Sale-Type Leases Minimum Lease Receivables	The minimum lease payments under sales-type leases are as follows:
		December 31,
		2014
		(In thousands)
	2015	$	6,188
	2016	4,832
	2017	3,803
	2018	2,174
	2019	619
	Total	$	17,616

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows:
		Automation and		Medication			Total
		Analytics		Adherence
		(In thousands)
	Net balance as of December 31, 2012	$	28,543	$	82,864		$	111,407
	Additions	—		—			—
	Adjustments (1)	—		(64		)	(64		)
	Net balance as of December 31, 2013	$	28,543	$	82,800		$	111,343
	Additions (2)	—		12,112			12,112
	Adjustments (3)	—		(735		)	(735		)
	Net balance as of December 31, 2014	$	28,543	$	94,177		$	122,720
	_________________________________________________
	(1)	Goodwill includes an immaterial adjustment related to the MTS acquisition in May 2012.
	(2)	Additions to goodwill as a result of the Surgichem acquisition in August 2014, including a $0.1 million adjustment to the purchase price in the fourth quarter of 2014.
	(3)	Adjustments reflect foreign currency exchange rate fluctuations.
Intangible Assets, Net	Intangible assets, net
		December 31, 2014									December 31, 2013
		Gross		Accumulated			Net			Useful Life	Gross Carrying		Accumulated			Net		Useful Life
		Carrying		Amortization			Carrying			(Years)	Amount		Amortization			Carrying		(Years)
		Amount					Amount									Amount
		(In thousands, except for years)
	Customer relationships	$	60,150	$	(7,919	)	$	52,231		30-May	$	54,730	$	(5,236	)	$	49,494	30-May
	Acquired technology	27,580		(4,068		)	23,512			20-Mar	27,580		(2,598		)	24,982		20-Mar
	Trade names	7,110		(1,576		)	5,534			12-Jan	6,890		(1,003		)	5,887		12-Mar
	Patents	1,655		(265		)	1,390			20	1,493		(254		)	1,239		20
	Non-compete agreements	—		—			—			—	60		(60		)	—		3
	Total intangibles assets, net	$	96,495	$	(13,828	)	$	82,667			$	90,753	$	(9,151	)	$	81,602
Future Amortization Expense for Intangible Assets	Total future amortization expense for intangible assets is as follows:
		December 31,
		2014
		(In thousands)
	2015	$	4,679
	2016	4,354
	2017	4,267
	2018	4,113
	2019	4,063
	Thereafter	61,191
	Total	$	82,667

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Capitalized software development costs, net of accumulated amortization of $14,918 and $10,547, respectively, and accumulated impairment (1)	$	19,643	$	13,660
	Technology license	1,678		2,350
	Long-term deposits	860		682
	Other long-term assets (2)	1,092		1,245
	Total other long-term assets	$	23,273	$	17,937
	_________________________________________________
	(1)	In the first quarter of 2013, we reorganized our management team as part of the continuing integration of MTS, including the software development department within the Medication Adherence segment. At this time, $1.8 million was capitalized as software development costs associated with a software solution that was intended to assist pharmacies in manual packaging of prescriptions. Our management team reassessed the viability of this project and the net realizable value of the capitalized costs in light of their decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities were needed to be added to the product before commercialization. This redesign was intended to provide a more robust global platform providing larger scalability and significant functionality not contained in the then-current beta version. We determined we could no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we abandoned the project and wrote off its net book value of $1.8 million, equating to $0.03 per diluted share, net of tax, which was recorded as an expense of research and development in our Consolidated Statements of Operations.
	(2)	Other long-term assets primarily include our equity investments. In the fourth quarter of 2014, we determined our equity investment accounted for under the cost method of accounting is no longer considered realizable, and therefore wrote off its net book value of $0.4 million as a non-operating expense in our Consolidated Statements of Operations.

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following:
		December 31,		December 31,
		2014		2013
		(In thousands)
	Rebates and lease buyouts	$	6,512	$	1,699
	Advance payments from customers	4,834		4,971
	Group purchasing organization fees	3,475		2,324
	Technology license purchase obligation	—		1,500
	Taxes payable	2,181		1,664
	Other accrued liabilities	2,297		1,588
	Total accrued liabilities	$	19,299	$	13,746

Deferred_Gross_Profit_Tables

Deferred Gross Profit (Tables)	12 Months Ended
	Dec. 31, 2014
Revenue Recognition [Abstract]
Schedule of Deferred Gross Profit	Deferred gross profit consists of the following:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Sales of medication and supply dispensing systems including packaging equipment (1)	$	36,947		$	29,040
	Less: cost of revenues, excluding installation costs	(8,389		)	(9,083		)
	Total deferred gross profit	$	28,558		$	19,957
	_________________________________________________
	(1)	Delivered and invoiced, pending installation.

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Rental on Non-Cancelable Operating Leases	The minimum future payments on non-cancelable operating leases are as follows:
		December 31,
		2014
		(In thousands)
	2015	$	5,637
	2016	5,590
	2017	4,873
	2018	4,711
	2019	4,836
	Thereafter	12,991
	Total minimum future lease payments	$	38,638

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The following is a geographical breakdown of income before the provision for income taxes:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	Domestic	$	48,327		$	34,678		$	25,794
	Foreign	177			351			1,281
	Income before provision for income taxes	$	48,504		$	35,029		$	27,075
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes consists of the following:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	Current:
	Federal	$	14,063		$	8,218		$	7,181
	State	2,274			1,621			1,006
	Foreign	192			447			154
	Total current income taxes	16,529			10,286			8,341
	Deferred:
	Federal	1,603			1,287			2,169
	State	84			(263		)	651
	Foreign	(230		)	(260		)	(264		)
	Total deferred income taxes	1,457			764			2,556
	Total provision for income taxes	$	17,986		$	11,050		$	10,897
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
		Year Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
		(In thousands)
	U.S. federal tax provision at statutory rate	$	16,998		$	12,260		$	9,476
	State taxes	1,533			883			1,077
	Non-deductible expenses	809			297			530
	Acquisition costs	229			—			431
	Share-based compensation expense	461			407			403
	Research tax credits	(818		)	(1,430		)	—
	Domestic production deduction	(1,127		)	(816		)	(601		)
	Other	(99		)	(551		)	(419		)
	Total provision for income taxes	$	17,986		$	11,050		$	10,897
Schedule of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets (liabilities) are as follows:
		December 31,			December 31,
		2014			2013
		(In thousands)
	Deferred tax assets (liabilities):
	Deferred revenue	$	12,639		$	11,074
	Stock compensation	6,287			7,447
	Inventory related items	2,713			2,947
	Tax credit carry forwards	2,168			3,160
	Reserves and accruals	327			—
	Loss carry forwards	12			64
	Other, net	—			5
	Subtotal	24,146			24,697
	Less: valuation allowance	—			(39		)
	Total net deferred tax assets	24,146			24,658
	Intangibles	(26,485		)	(26,604		)
	Depreciation and amortization	(14,331		)	(12,077		)
	Reserves and accruals	—			(353		)
	Other, net	(194		)	—
	Total deferred tax liabilities	(41,010		)	(39,034		)
	Net deferred tax liabilities	$	(16,864	)	$	(14,376	)
Schedule of Unrecognized Tax Benefits	The aggregate change in the balance of gross unrecognized tax benefits, which excludes interest and penalties, is as follows:
		(In thousands)
	Year Ended December 31, 2011	$	5,796
	Increases related to tax positions taken during a prior period	43
	Increases related to tax positions related to MTS	1,066
	Decreases related to tax positions taken during the prior period	—
	Increases related to tax positions taken during the current period	422
	Decreases related to settlements	(33		)
	Decreases related to expiration of statute of limitations	(379		)
	Year Ended December 31, 2012	$	6,915
	Increases related to tax positions taken during a prior period	406
	Decreases related to tax positions taken during the prior period	(79		)
	Increases related to tax positions taken during the current period	764
	Decreases related to settlements	—
	Decreases related to expiration of statute of limitations	(32		)
	Year Ended December 31, 2013	$	7,974
	Increases related to tax positions taken during a prior period	63
	Decreases related to tax positions taken during the prior period	(89		)
	Increases related to tax positions taken during the current period	801
	Decreases related to settlements	—
	Decreases related to expiration of statute of limitations	(264		)
	Year Ended December 31, 2014	$	8,485

Stock_Repurchases_Tables

Stock Repurchases (Tables)	12 Months Ended
	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Stock Repurchases	The following table summarizes our stock repurchases:
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands, except per share data)
	Total number of shares repurchased	884		885		898
	Dollar amount of shares repurchased	$	24,091	$	20,962	$	12,363
	Average price paid per share	$	27.24	$	23.7	$	13.76

Employee_Benefits_and_ShareBas1

Employee Benefits and Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Estimate of Fair Value of Share-Based Awards, Stock Options	The following assumptions were used to estimate the fair value of share-based awards:
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Stock Option Plans
	Risk-free interest rate (1)	1.6	%	1.2	%		0.9	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	34.9	%	43.1	%		45.8	%
	Expected life (3)	4.8 years		5.3 years			5.2 years
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Employee Stock Purchase Plan
	Risk-free interest rate (1)	0.2	%	0.2	%		0.2	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	33.2	%	35.1	%		38.5	%
	Expected life (3)	0.5 - 2 years		0.5 - 2 years			0.5 - 2 years
	_________________________________________________
	(1)	The risk-free interest rate for both stock options and the ESPP is based on the zero-coupon U.S. Treasury rate curve in effect at the time of the option grant or at the beginning of the ESPP offering period.
	(2)	Expected volatility for both stock options and the ESPP reflects a combination of historical and market-based implied volatility consistent with ASC 718 and SEC Staff Accounting Bulletin 107. We determined that the combination of historical and market-based implied volatility provides a more accurate reflection of our market conditions and is more representative of future stock price trends than employing solely historical volatility.
	(3)	Represents the period of time that options granted are expected to be outstanding, which is derived from historical data on employee exercise and post-vesting employment termination behavior.
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	The following assumptions were used to estimate the fair value of share-based awards:
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Stock Option Plans
	Risk-free interest rate (1)	1.6	%	1.2	%		0.9	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	34.9	%	43.1	%		45.8	%
	Expected life (3)	4.8 years		5.3 years			5.2 years
		Year Ended
		December 31,		December 31,			December 31,
		2014		2013			2012
	Employee Stock Purchase Plan
	Risk-free interest rate (1)	0.2	%	0.2	%		0.2	%
	Dividend yield	—	%	—	%		—	%
	Expected volatility (2)	33.2	%	35.1	%		38.5	%
	Expected life (3)	0.5 - 2 years		0.5 - 2 years			0.5 - 2 years
	_________________________________________________
	(1)	The risk-free interest rate for both stock options and the ESPP is based on the zero-coupon U.S. Treasury rate curve in effect at the time of the option grant or at the beginning of the ESPP offering period.
	(2)	Expected volatility for both stock options and the ESPP reflects a combination of historical and market-based implied volatility consistent with ASC 718 and SEC Staff Accounting Bulletin 107. We determined that the combination of historical and market-based implied volatility provides a more accurate reflection of our market conditions and is more representative of future stock price trends than employing solely historical volatility.
	(3)	Represents the period of time that options granted are expected to be outstanding, which is derived from historical data on employee exercise and post-vesting employment termination behavior.
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in our Consolidated Statements of Income:
		Year Ended
		December 31,			December 31,				December 31,
		2014			2013				2012
		(In thousands)
	Cost of product and service revenues	$	1,456		$	1,241			$	1,011
	Research and development	1,655			1,359				889
	Selling, general and administrative	9,674			8,551				7,314
	Total share-based compensation expense	$	12,785		$	11,151			$	9,214
Stock Option Activity under the 2009 Plan	A summary of the stock option activity under the 2009 Plan is presented below:
		Number of		Weighted-Average				Weighted-Average		Aggregate
		Shares		Exercise Price				Remaining Years		Intrinsic Value(1)
		(In thousands, except per share data)
	Outstanding at December 31, 2013	3,143		$	15.82			5.6
	Granted	641		28.11
	Exercised	(1,007	)	14.74
	Expired	(12	)	19.88
	Forfeited	(93	)	19.97
	Outstanding at December 31, 2014	2,672		$	19.02			6.5		$	37,692
	Exercisable at December 31, 2014	1,514		$	15.66			4.7		$	26,447
	Vested and expected to vest at December 31, 2014	2,640		$	18.92			6.4		$	37,481
	_________________________________________________
	(1)	Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the year as reported by the NASDAQ Global Select Market, and the exercise price of the option.
Restricted Stock Units Activity under the 2009 Plan	A summary of the restricted stock activity under the 2009 Plan is presented below:
		Number of		Weighted-Average				Weighted-Average		Aggregate
		Shares		Grant Date Fair Value				Remaining Years		Intrinsic Value
		(In thousands, except per share data)
	Restricted Stock Units
	Outstanding at December 31, 2013	362		$	17.15			2.5
	Granted	238		28.88
	Vested	(181	)	17.51
	Forfeited	(20	)	16.5
	Outstanding and unvested at December 31, 2014	399		$	24			1.5		$	13,190
	Expected to vest at December 31, 2014	387						1.5		$	12,807
Restricted Stock Units Award under the 2009 Plan
		Number of		Weighted-Average
		Shares		Grant Date Fair Value
		(In thousands, except per share data)
	Restricted Stock Awards
	Outstanding at December 31, 2013	52		$	18.43
	Granted	38		26.42
	Vested	(54	)	18.68
	Forfeited	—		—
	Outstanding and unvested at December 31, 2014	36		$	26.47
Performance Shares Restricted Stock Activity under the 2009 Plan	A summary of the performance-based restricted stock activity under the 2009 Plan is presented below:
		Number of		Weighted-Average
		Shares		Grant Date Fair Value Per Unit
		(In thousands, except per share data)
	Unvested at December 31, 2013	225		$	13.32
	Granted	158		20.94
	Vested	(114	)	13.32
	Cancelled	(36	)	16.73
	Unvested at December 31, 2014	233		$	17.96

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following table summarizes the financial performance of our reporting segments:
		Year Ended
		December 31, 2014						December 31, 2013						31-Dec-12
		Automation and		Medication		Total		Automation and		Medication		Total		Automation and		Medication		Total
		Analytics		Adherence (1)				Analytics		Adherence				Analytics		Adherence (2)
		(In thousands)
	Revenues	$	354,095	$	86,805	$	440,900	$	302,917	$	77,668	$	380,585	$	260,160	$	53,867	$	314,027
	Cost of revenues	151,327		55,713		207,040		129,314		47,872		177,186		111,599		31,840		143,439
	Gross profit	202,768		31,092		233,860		173,603		29,796		203,399		148,561		22,027		170,588
	Operating expenses	155,156		29,121		184,277		140,087		28,013		168,100		127,467		15,995		143,462
	Income from operations	$	47,612	$	1,971	$	49,583	$	33,516	$	1,783	$	35,299	$	21,094	$	6,032	$	27,126
	_________________________________________________
	(1)	Includes Surgichem results as of August 2014.
	(2)	Includes MTS results as of May 2012.
Revenue by Geographical Location	Geographical Information
		Year Ended
		December 31,		December 31,		December 31,
		2014		2013		2012
		(In thousands)
	United States	$	394,234	$	334,412	$	287,716
	Foreign countries (1)	46,666		46,173		26,311
	Total revenues	$	440,900	$	380,585	$	314,027
	_________________________________________________
	(1)	No individual country represented more than 10% of the respective totals.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
	customer	customer	customer
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence (VSOE) exist when (approximately 80% or more) standalone sales are within a reasonable price range	80.00%
Investments under cost method	$400,000	$400,000
Investments under equity method	900,000
Percentage of ownership purchased of United Kingdom automation and analytics of distributors	15.00%
Number of significant customers that accounted for more than 10% of accounts receivables	0	0	0
Transferred non-recourse accounts receivables	62,000,000	41,300,000	60,900,000
Accounts receivables from third-party leasing companies for transferred non-recourse accounts receivables	1,100,000	100,000	700,000
Cost of application development of enterprise-level software	19,643,000	13,660,000
Capitalized software development costs	87,677,000	75,682,000
Computer Equipment [Member]
Accounting Policies [Line Items]
Useful life	5 years
Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Capitalized software development costs	5,689,000	5,260,000
Equipment [Member]
Accounting Policies [Line Items]
Capitalized software development costs	42,829,000	40,180,000
Software Development [Member]
Accounting Policies [Line Items]
Capitalized software development costs	28,920,000	20,199,000
Cost of revenues for amortization of capitalized software development cost	4,400,000	3,200,000	2,300,000
Maximum [Member]
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)	15.00%
Finite-Lived Intangible Asset, Useful Life	30 years
Maximum [Member] | Computer Equipment [Member]
Accounting Policies [Line Items]
Useful life	5 years
Maximum [Member] | Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Useful life	7 years
Maximum [Member] | Equipment [Member]
Accounting Policies [Line Items]
Useful life	12 years
Minimum [Member]
Accounting Policies [Line Items]
Vendor-Specific Objective Evidence, within a reasonably narrow price range (plus or minus of median rate)	15.00%
Finite-Lived Intangible Asset, Useful Life	1 year
Minimum [Member] | Computer Equipment [Member]
Accounting Policies [Line Items]
Useful life	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Useful life	5 years
Minimum [Member] | Equipment [Member]
Accounting Policies [Line Items]
Useful life	3 years
Revolving Credit Facility [Member] | Wells Fargo Bank, National Association [Member] | Line of Credit [Member]
Accounting Policies [Line Items]
Revolving credit facility				75,000,000
Property and Equipment [Member]
Accounting Policies [Line Items]
Cost of application development of enterprise-level software	3,900,000	4,800,000
Other Assets [Member] | Software Development [Member]
Accounting Policies [Line Items]
Capitalized software development costs	10,400,000	7,800,000
Selling, General and Administrative Expenses [Member]
Accounting Policies [Line Items]
Shipping and handling expenses	$7,400,000	$6,100,000	$4,100,000

Business_Combinations_Schedule

Business Combinations - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed, Surgichem (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 22, 2014
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$122,720	$111,343	$111,407
Surgichem [Member]
Business Acquisition [Line Items]
Cash				153
Accounts receivable				2,462
Inventory				2,190
Deferred tax assets and other current assets				361
Total current assets				5,166
Property and equipment				164
Intangible assets				5,730
Goodwill				12,112
Total assets				23,172
Current liabilities				1,191
Long-term deferred tax liabilities				1,104
Total purchase price				$20,877

Business_Combinations_Schedule1

Business Combinations - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed, MedPak (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	21-May-12
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$122,720	$111,343	$111,407
MedPak Holdings, Inc. [Member]
Business Acquisition [Line Items]
Cash				2,000
Accounts receivable				7,403
Inventory				11,726
Deferred tax assets and other current assets				2,894
Total current assets				24,023
Property and equipment				9,807
Intangible assets				83,900
Goodwill				82,800
Other long-term assets				308
Total assets				200,838
Current liabilities				-7,917
Long-term deferred tax liabilities				-33,386
Other long-term liabilities				-1,223
Total purchase price				$158,312

Business_Combinations_FiniteLi

Business Combinations - Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) (MedPak Holdings, Inc. [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	21-May-12	21-May-12
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	$83,900	$83,900
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	6,800	6,800
Useful Life (Years)	12 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	50,500	50,500
Acquired Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	$26,600	$26,600
Useful Life (Years)	20 years
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	12 years
Minimum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	28 years
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	30 years
Maximum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	30 years

Business_Combinations_Addition

Business Combinations - Additional Information (Details) (USD $)	12 Months Ended			0 Months Ended	4 Months Ended	0 Months Ended	7 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 22, 2014	Dec. 31, 2014	21-May-12	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition	$20,723,000	$0	$156,312,000
Goodwill	122,720,000	111,343,000	111,407,000		122,720,000		111,407,000
Surgichem [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition				20,700,000
Cash acquired from Acquisition				200,000
Intangible assets acquired				5,730,000
Goodwill				12,112,000
Acquisition generated revenue					4,600,000
Income (Loss) from operations					-100,000
Total revenue	13,300,000	11,900,000
Acquisition deferred tax liabilities				1,104,000
Surgichem [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired				5,400,000
Acquired intangible assets, useful life (in years)				18 years
Surgichem [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired				300,000
Acquired intangible assets, useful life (in years)				1 year
MedPak Holdings, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price of acquisition						156,300,000
Cash acquired from Acquisition						2,000,000
Intangible assets acquired						83,900,000
Goodwill						82,800,000
Acquisition generated revenue							47,200,000
Income (Loss) from operations							2,900,000
Acquisition deferred tax liabilities						33,386,000
MedPak Holdings, Inc. [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired						50,500,000
MedPak Holdings, Inc. [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired						6,800,000
Acquired intangible assets, useful life (in years)						12 years
Minimum [Member] | MedPak Holdings, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets, useful life (in years)						12 years
Minimum [Member] | MedPak Holdings, Inc. [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets, useful life (in years)						28 years
Maximum [Member] | MedPak Holdings, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets, useful life (in years)						30 years
Maximum [Member] | MedPak Holdings, Inc. [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets, useful life (in years)						30 years
Selling, General and Administrative Expenses [Member] | Surgichem [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Acquisition Related Costs	1,100,000
Acquisition expense reimbursement	-500,000				-500,000
Selling, General and Administrative Expenses [Member] | MedPak Holdings, Inc. [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Acquisition Related Costs		$3,200,000

Net_Income_Per_Share_Basic_and

Net Income Per Share - (Basic and Diluted Net Income Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net income	$30,518	$23,979	$16,178
Weighted-average shares outstanding — basic	35,650	34,736	33,307
Add: Dilutive effect of employee stock plans	972	1,041	906
Weighted-average shares outstanding — diluted	36,622	35,777	34,213
Net income per share — basic	$0.86	$0.69	$0.49
Net income per share — diluted	$0.83	$0.67	$0.47
Anti-dilutive weighted-average shares related to stock award plans	640	850	2,149

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets Measured at Fair Value On A Recurring Basis (Details) (Fair Value, Measurements, Recurring [Member], Fair Value, Inputs, Level 1 [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	$61,311	$38,823
Cash equivalents	64,577	65,708
Total cash and cash equivalents	$125,888	$104,531

Inventories_Additional_Informa

Inventories - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Raw materials	$8,254,000	$10,765,000
Work in process	64,000	534,000
Finished goods	23,236,000	20,158,000
Total inventories, net	31,554,000	31,457,000
Primary Supplier [Member]
Concentration Risk [Line Items]
Minimum supplier purchase obligations	0
Notice of termination, time upon delivery	2 months
Purchases from supplier	$34,500,000	$29,200,000	$23,800,000

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$87,677,000	$75,682,000
Accumulated depreciation and amortization	-51,499,000	-40,428,000
Total property and equipment, net	36,178,000	35,254,000
Depreciation and amortization	11,300,000	10,900,000	8,000,000
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	42,829,000	40,180,000
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	5,689,000	5,260,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	8,701,000	7,394,000
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	28,920,000	20,199,000
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$1,538,000	$2,649,000

Net_Investment_in_SalesType_Le2

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Terms of sales-type leases (generally up to five years in length)	5 years
Net minimum lease payments to be received	$17,616,000	$18,172,000
Less: unearned interest income portion	-1,131,000	-1,455,000
Net investment in sales-type leases	16,485,000	16,717,000
Less: short-term portion	-5,637,000	-5,232,000
Long-term net investment in sales-type leases	10,848,000	11,485,000
Collective allowance for credit losses	$200,000	$200,000

Net_Investment_in_SalesType_Le3

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Leases [Abstract]
2015	$6,188
2016	4,832
2017	3,803
2018	2,174
2019	619
Total	$17,616

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) (USD $)	12 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Aug. 22, 2014
Goodwill [Roll Forward]
Net balance as of December 31,	$111,343,000	$111,407,000
Additions	12,112,000	0
Adjustments	-735,000	-64,000
Net balance as of December 31,	122,720,000	111,343,000	122,720,000
Automation and Analytics [Member]
Goodwill [Roll Forward]
Net balance as of December 31,	28,543,000	28,543,000
Additions	0	0
Adjustments	0	0
Net balance as of December 31,	28,543,000	28,543,000	28,543,000
Medication Adherence [Member]
Goodwill [Roll Forward]
Net balance as of December 31,	82,800,000	82,864,000
Additions	12,112,000	0
Adjustments	-735,000	-64,000
Net balance as of December 31,	94,177,000	82,800,000	94,177,000
Surgichem [Member]
Goodwill [Roll Forward]
Net balance as of December 31,				12,112,000
Net balance as of December 31,				12,112,000
Surgichem Acquisition, adjustment to purchase price			$100,000

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Intangible Assets, Net (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$96,495	$90,753
Finite-Lived Intangible Assets, Accumulated Amortization	-13,828	-9,151
Total intangibles assets, net carrying amount	82,667	81,602
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	60,150	54,730
Finite-Lived Intangible Assets, Accumulated Amortization	-7,919	-5,236
Total intangibles assets, net carrying amount	52,231	49,494
Acquired Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	27,580	27,580
Finite-Lived Intangible Assets, Accumulated Amortization	-4,068	-2,598
Total intangibles assets, net carrying amount	23,512	24,982
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	7,110	6,890
Finite-Lived Intangible Assets, Accumulated Amortization	-1,576	-1,003
Total intangibles assets, net carrying amount	5,534	5,887
Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,655	1,493
Finite-Lived Intangible Assets, Accumulated Amortization	-265	-254
Total intangibles assets, net carrying amount	1,390	1,239
Useful Life	20 years	20 years
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	0	60
Finite-Lived Intangible Assets, Accumulated Amortization	0	-60
Total intangibles assets, net carrying amount	$0	$0
Useful Life		3 years
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	30 years
Maximum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	30 years	30 years
Maximum [Member] | Acquired Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years	20 years
Maximum [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year
Minimum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years	5 years
Minimum [Member] | Acquired Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Minimum [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	3 years

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$4,679
2016	4,354
2017	4,267
2018	4,113
2019	4,063
Thereafter	61,191
Total intangibles assets, net carrying amount	$82,667	$81,602

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Additional Information (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$4.60	$4.30	$2.90
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized cost of third-party cost for internally-developed patents	$0.30	$0.40	$0.40

Other_Assets_Additional_Inform

Other Assets - Additional Information (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Capitalized software development costs, net of accumulated amortization of $14,918 and $10,547, respectively, and accumulated impairment	$19,643,000		$13,660,000
Technology license	1,678,000		2,350,000
Long-term deposits	860,000		682,000
Other long-term assets	1,092,000		1,245,000
Total other long-term assets	23,273,000		17,937,000
Accumulated amortization of capitalized software development costs	14,918,000		10,547,000
Capitalized software development costs associated with software solution		1,800,000
Net of tax impact of abandoning the project and writing off its net book value (diluted per share amount)		$0.03
Write off of equity investment no longer realizable, net book value	400,000
Research and development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net		$1,800,000

Accrued_Liabilities_Additional

Accrued Liabilities - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Rebates and lease buyouts	$6,512	$1,699
Advance payments from customers	4,834	4,971
Group purchasing organization fees	3,475	2,324
Technology license purchase obligation	0	1,500
Taxes payable	2,181	1,664
Other accrued liabilities	2,297	1,588
Total accrued liabilities	$19,299	$13,746

Deferred_Gross_Profit_Addition

Deferred Gross Profit - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total deferred gross profit	$28,558	$19,957
Products with Installation Services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales of medication and supply dispensing systems including packaging equipment	36,947	29,040
Less: cost of revenues, excluding installation costs	-8,389	-9,083
Total deferred gross profit	$28,558	$19,957

Commitments_Minimum_future_ren

Commitments - Minimum future rental on non-cancelable operating leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$6,800,000	$6,900,000	$5,700,000
2015	5,637,000
2016	5,590,000
2017	4,873,000
2018	4,711,000
2019	4,836,000
Thereafter	12,991,000
Total minimum future lease payments	38,638,000
Purchase obligation due in the next twelve months	$9,300,000

Contingencies_Additional_Infor

Contingencies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Standard product warranty, duration following installation	30 days
Medication packaging system duration of limited warranties	6 months

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Tax Credit Carryforward [Line Items]
Undistributed foreign earnings	$0.80
Income tax expense, if undistributed foreign earnings are distributed	0.3
Impact to tax expense if unrecognized tax benefit is realized	7.3
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	$7.90

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Domestic	$48,327	$34,678	$25,794
Foreign	177	351	1,281
Income before provision for income taxes	$48,504	$35,029	$27,075

Income_Taxes_Schedule_of_Compo

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$14,063	$8,218	$7,181
State	2,274	1,621	1,006
Foreign	192	447	154
Total current income taxes	16,529	10,286	8,341
Deferred:
Federal	1,603	1,287	2,169
State	84	-263	651
Foreign	-230	-260	-264
Total deferred income taxes	1,457	764	2,556
Total provision for income taxes	$17,986	$11,050	$10,897

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
U.S. federal tax provision at statutory rate	$16,998	$12,260	$9,476
State taxes	1,533	883	1,077
Non-deductible expenses	809	297	530
Acquisition costs	229	0	431
Share-based compensation expense	461	407	403
Research tax credits	-818	-1,430	0
Domestic production deduction	-1,127	-816	-601
Other	-99	-551	-419
Total provision for income taxes	$17,986	$11,050	$10,897

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets (liabilities):
Deferred revenue	$12,639	$11,074
Stock compensation	6,287	7,447
Inventory related items	2,713	2,947
Tax credit carry forwards	2,168	3,160
Reserves and accruals	327	0
Loss carry forwards	12	64
Other, net	0	5
Subtotal	24,146	24,697
Less: valuation allowance	0	-39
Total net deferred tax assets	24,146	24,658
Intangibles	-26,485	-26,604
Depreciation and amortization	-14,331	-12,077
Reserves and accruals	0	-353
Other, net	-194	0
Total deferred tax liabilities	-41,010	-39,034
Net deferred tax liabilities	($16,864)	($14,376)

Income_Taxes_Schedule_of_Unrec

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the Period Balance	$7,974	$6,915	$5,796
Increases related to tax positions taken during a prior period	63	406	43
Increases related to tax positions related to MTS			1,066
Decreases related to tax positions taken during the prior period	-89	-79	0
Increases related to tax positions taken during the current period	801	764	422
Decreases related to settlements	0	0	-33
Decreases related to expiration of statute of limitations	-264	-32	-379
End of the Period Balance	$8,485	$7,974	$6,915

Stock_Repurchases_Additional_I

Stock Repurchases - Additional Information (Details) (USD $)	12 Months Ended			29 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Aug. 31, 2012	Nov. 30, 2014
Equity, Class of Treasury Stock [Line Items]
Total number of shares repurchased	884	885	898
Dollar amount of shares repurchased	$24,091,000	$20,962,000	$12,363,000
Average price paid per share	$27.24	$23.70	$13.76
Stock repurchases program, remaining authorized repurchase amount	54,900,000			54,900,000
August 2012 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount					50,000,000
Stock repurchases program, amount repurchased				45,100,000
November 2014 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount						$50,000,000

Employee_Benefits_and_ShareBas2

Employee Benefits and Share-Based Compensation - Stock Purchase Plan (Details) (1997 Employee Stock Purchase Plan [Member], Employee Stock [Member], USD $)	0 Months Ended	12 Months Ended
Share data in Millions, unless otherwise specified	19-May-09	Dec. 31, 2014
1997 Employee Stock Purchase Plan [Member] | Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage of earnings allowed for purchase of shares		15.00%
Maximum amount of annual salary permitted to utilize		$25,000
Purchase price of common stock, percent		85.00%
Offering period		24 months
Purchase period		6 months
Shares added to reserved for future issuance	2.6
Shares reserved for future issuance		0.6
Share of common stock purchased		0.5
Shares issued for the 1997 Employee Stock Purchase Plan		4.7
Unrecognized compensation cost		$1,800,000
Weighted average period of compensation cost recognized		8 months 12 days

Employee_Benefits_and_ShareBas3

Employee Benefits and Share-Based Compensation - Stock Award Plans (Details)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jan. 22, 2013

Dec. 31, 2014

Feb. 28, 2014

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2014

Feb. 05, 2014

Dec. 16, 2010

Oct. 01, 2010

19-May-09

Dec. 31, 2013

Jan. 17, 2012

Mar. 20, 2014

Dec. 31, 2012

Day

Day

Day

Day

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares authorized for issuance

132,500

Performance Period

1 year

Period used to calculate annual rates of return

1 year

Trading days

20

20

20

20

Percentile rank of stockholder return

35.30%

Performance Shares [Member] | Vesting years subsequent the date of grant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

3 years

2009 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares authorized for issuance

2,600,000

2,100,000

Reduction to share available for issuance (in per share)

1

1.8

1.4

1.4

Increase to shares authorized

2,500,000

Shares reserved for future issuance

1,800,000

1,800,000

2009 Plan [Member] | Vesting one year from the vesting commencement date [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of award vesting

25.00%

2009 Plan [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

Expiration period

10 years

2009 Plan [Member] | Employee Stock Option [Member] | Vesting one year from the vesting commencement date [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

2009 Plan [Member] | Employee Stock Option [Member] | Vesting in equal monthly installments [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Monthly vesting installments

36

2009 Plan [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

4 years

Shares granted

238,000

Vested

181,000

2009 Plan [Member] | Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted

158,000

Vested

114,000

2011 Performance Based Restricted Stock Units [Member] | Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Awards eligible for vesting

120,000

120,000

Vested

30,000

Percentile rank of stockholder return

76.30%

Percentage of shares eligible for time-based vesting

120.00%

2011 Performance Based Restricted Stock Units [Member] | Performance Shares [Member] | Vested immediately [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of award vesting

25.00%

25.00%

2012 Performance Based Restricted Stock Units [Member] | Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Awards eligible for vesting

62,500

Vested

15,600

Percentage of shares eligible for time-based vesting

50.00%

2012 Performance Based Restricted Stock Units [Member] | Performance Shares [Member] | Vested immediately [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Percentage of award vesting

25.00%

2013 Performance Based Restricted Stock Units [Member] | Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Awards eligible for vesting

137,500

Percentile rank of stockholder return

63.90%

Percentage of shares eligible for time-based vesting

100.00%

2013 Performance Based Restricted Stock Units [Member] | Performance Shares [Member] | Vested immediately [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Awards eligible for vesting

137,500

Vested

68,750

Percentage of award vesting

25.00%

Officer [Member] | Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares granted

132,500

137,500

125,000

Awards eligible for vesting

62,500

Employee_Benefits_and_ShareBas4

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.60%	1.20%	0.90%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	34.90%	43.10%	45.80%
Expected life	4 years 9 months 18 days	5 years 3 months 18 days	5 years 2 months 12 days
Employee Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	6 months	6 months	6 months
Employee Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	2 years	2 years	2 years
1997 Employee Stock Purchase Plan [Member] | Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.20%	0.20%	0.20%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	33.20%	35.10%	38.50%

Employee_Benefits_and_ShareBas5

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) (2009 Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$12,785,000	$11,151,000	$9,214,000
Income tax benefit	4,500,000	2,400,000	2,600,000
Cost of product and service revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,456,000	1,241,000	1,011,000
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,655,000	1,359,000	889,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$9,674,000	$8,551,000	$7,314,000

Employee_Benefits_and_ShareBas6

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) (2009 Plan [Member], USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Outstanding at December 31, 2013	3,143
Granted	641
Exercised	-1,007
Expired	-12
Forfeited	-93
Outstanding at December 31, 2014	2,672	3,143
Exercisable at December 31, 2014	1,514
Vested and expected to vest at December 31, 2014	2,640
Weighted Average Exercise Price
Outstanding at December 31, 2013	$15.82
Granted	$28.11
Exercised	$14.74
Expired	$19.88
Forfeited	$19.97
Outstanding at December 31, 2014	$19.02	$15.82
Exercisable at December 31, 2014	$15.66
Vested and expected to vest at December 31, 2014	$18.92
Outstanding at December 31 (in years)	6 years 6 months	5 years 7 months 6 days
Exercisable at December 31, 2014 (in years)	4 years 8 months 12 days
Vested and expected to vest at December 31, 2014 (in years)	6 years 4 months 24 days
Outstanding at December 31, 2014	$37,692,000
Exercisable at December 31, 2014	26,447,000
Vested and expected to vest at December 31, 2014	37,481,000
Employee Stock Option [Member]
Weighted Average Exercise Price
Weighted-average fair value (in usd per share)	$9.12	$8.09	$6.13
Intrinsic value of options exercised	14,100,000	14,000,000	2,800,000
Unrecognized compensation cost of unvested stock options	$8,800,000
Weighted average period of compensation cost recognized	2 years 9 months 18 days

Employee_Benefits_and_ShareBas7

Employee Benefits and Share-Based Compensation - Related Stock Activity (Details) (2009 Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units (RSUs) [Member]
Number of Shares
Outstanding and unvested December 31	362,000
Granted	238,000
Vested	-181,000
Forfeited	-20,000
Outstanding and unvested at December 31	399,000	362,000
Expected to vest at December 31, 2014	387,000
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$17.15
Granted	$28.88	$19.87	$14.58
Vested	$17.51
Forfeited	$16.50
Outstanding and unvested at December 31	$24	$17.15
Expected to vest at December 31, 2014 (in years)	1 year 5 months 13 days
Outstanding and unvested at December 31, 2014 (in years)	1 year 5 months 16 days	2 years 6 months
Aggregate Intrinsic Value
Outstanding and unvested at December 31, 2014	$13,190,000
Expected to vest at December 31, 2014	12,807,000
Fair value of restricted stock units	3,200,000	4,400,000	2,300,000
Unrecognized compensation cost	8,700,000
Weighted average period of compensation cost recognized	2 years 7 months 6 days
Restricted Stock [Member]
Number of Shares
Outstanding and unvested December 31	52,000
Granted	38,000
Vested	-54,000
Forfeited	0
Outstanding and unvested at December 31	36,000	52,000
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$18.43
Granted	$26.42	$18.20	$14.19
Vested	$18.68
Forfeited	$0
Outstanding and unvested at December 31	$26.47	$18.43
Aggregate Intrinsic Value
Fair value of restricted stock units	1,000,000	1,100,000	1,100,000
Unrecognized compensation cost	$400,000
Weighted average period of compensation cost recognized	6 months

Employee_Benefits_and_ShareBas8

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Units Awards (Details) (2009 Plan [Member], Performance Shares [Member], USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
2009 Plan [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of compensation cost recognized	1 year 2 months 12 days
Fair value of restricted stock units	$1.50	$0.70	$0.70
Unrecognized compensation cost	$2
Number of Shares
Outstanding and unvested December 31	225,000
Granted	158,000
Vested	-114,000
Forfeited	-36,000
Outstanding and unvested at December 31	233,000	225,000
Weighted-Average Grant Date Fair Value
Outstanding and unvested December 31	$13.32
Granted	$20.94	$14.68	$10.94
Vested	$13.32
Forfeited	$16.73
Outstanding and unvested at December 31	$17.96	$13.32

Employee_Benefits_and_ShareBas9

Employee Benefits and Share-Based Compensation - 401(k) Plan (Details) (Omnicell Plan [Member], USD $)	12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012	Jan. 01, 2015
Defined Contribution Plan Disclosure [Line Items]
Maximum employee annual contribution, percentage of earnings	75.00%
Other Postretirement Benefit Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum employee annual contribution, percentage of earnings		75.00%
Percentage of employer maximum matching contribution	3.00%
Maximum amount of employer contribution	1,000	1,500
Employer matching contribution, percent of employee contribution		50.00%
401(k) contributions	1.1	$1.30	$0.80
Other Postretirement Benefit Plan [Member] | Subsequent Event [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum amount of employer contribution				2,000
Employer matching contribution, percent of employee contribution				50.00%

Recovered_Sheet1

Employee Benefits and Share-Based Compensation - Preferred Stock (Details)	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Segment_Information_Additional

Segment Information - Additional Information (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	segment	customer	customer	customer
		segment
Segment Reporting Information [Line Items]
Number of segments	2	2
Number of reportable segments		2
Number of significant customers that accounted for more than 10% of accounts receivables		0	0	0

Segment_Information_Financial_

Segment Information - Financial Performance of Reporting Segments (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenues	$440,900	$380,585	$314,027
Cost of revenues	207,040	177,186	143,439
Gross profit	233,860	203,399	170,588
Operating expenses	184,277	168,100	143,462
Income from operations	49,583	35,299	27,126
Automation and Analytics [Member]
Segment Reporting Information [Line Items]
Revenues	354,095	302,917	260,160
Cost of revenues	151,327	129,314	111,599
Gross profit	202,768	173,603	148,561
Operating expenses	155,156	140,087	127,467
Income from operations	47,612	33,516	21,094
Medication Adherence [Member]
Segment Reporting Information [Line Items]
Revenues	86,805	77,668	53,867
Cost of revenues	55,713	47,872	31,840
Gross profit	31,092	29,796	22,027
Operating expenses	29,121	28,013	15,995
Income from operations	$1,971	$1,783	$6,032

Segment_Information_Revenue_by

Segment Information - Revenue by Geographical Location (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$440,900	$380,585	$314,027
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	394,234	334,412	287,716
Foreign Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$46,666	$46,173	$26,311

Credit_Agreement_Additional_In

Credit Agreement - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2013	Nov. 05, 2014	Nov. 04, 2014
Line of Credit [Member] | Revolving Credit Facility [Member] | Wells Fargo Bank, National Association [Member]
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit		$75,000,000
Line of Credit [Member] | Letter of Credit [Member] | Wells Fargo Bank, National Association [Member]
Debt Instrument [Line Items]
Revolving credit facility with a letter of credit sub limit		10,000,000
Increases in to aggregate commitments (does not exceed $25 million)		25,000,000
Commitment fee percentage	0.25%
Eurodollar [Member] | Line of Credit [Member] | Letter of Credit [Member] | Wells Fargo Bank, National Association [Member]
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate	1.75%
Federal Funds Effective Swap Rate [Member] | Line of Credit [Member] | Letter of Credit [Member] | Wells Fargo Bank, National Association [Member]
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate	0.50%
London Interbank Offered Rate (LIBOR) [Member] | Line of Credit [Member] | Letter of Credit [Member] | Wells Fargo Bank, National Association [Member]
Debt Instrument [Line Items]
Amounts draw under the Credit Agreements bears interest rate	1.75%
November 2014 Stock Repurchase Program [Member]
Debt Instrument [Line Items]
Authorized amount of repurchase of common stock			$50,000,000	$25,000,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Mar. 19, 2015	Feb. 27, 2015	Feb. 26, 2015
	Executive_Officer
Subsequent Event [Member]
Subsequent Event [Line Items]
Total aggregate consideration			$18,000,000
Cost incurred of certain discounts and Omnicell products allegedly provided		$0
Number of executive officers in the Nelson v. Omnicell putative class action lawsuit	2

Schedule_II_Valuation_and_Qual1

Schedule II Valuation and Qualifying Accounts - Schedule of Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$657	$1,329	$727
Charged to Cost and Expenses	941	244	741
Credited to Other Accounts	-65	-67	-57
Amount Written Off	-165	-849	-82
Balance at End of Period	1,368	657	1,329
Accounts Receivable [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	490	722	443
Charged to Cost and Expenses	941	195	316
Credited to Other Accounts	-60	-67	-57
Amount Written Off	-165	-360	20
Balance at End of Period	1,206	490	722
Investment in Sales-Type Leases [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	167	607	284
Charged to Cost and Expenses	0	49	425
Credited to Other Accounts	-5	0	0
Amount Written Off	0	-489	-102
Balance at End of Period	$162	$167	$607